Review



mouse cxcl12 sdf 1 alpha quantikine elisa kit  (R&D Systems)


Bioz Verified Symbol R&D Systems is a verified supplier
Bioz Manufacturer Symbol R&D Systems manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 95

    Structured Review

    R&D Systems mouse cxcl12 sdf 1 alpha quantikine elisa kit
    Mouse Cxcl12 Sdf 1 Alpha Quantikine Elisa Kit, supplied by R&D Systems, used in various techniques. Bioz Stars score: 95/100, based on 141 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/mouse+cxcl12+sdf+1+alpha+quantikine+elisa+kit/Mouse+CXCL12%2FSDF-1+alpha+Quantikine+ELISA+Kit/bio_rxiv__64898__2026__04__21__720007-284-6-12
    Average 95 stars, based on 141 article reviews
    mouse cxcl12 sdf 1 alpha quantikine elisa kit - by Bioz Stars, 2026-11
    95/100 stars

    Images

    Related Articles

    BIA-KA:

    Article Title: A Bioinstructive Injectable Hydrogel for Enhancing Intrinsic Regeneration through Cell Recruitment and Training
    Article Snippet: .. DPBS was periodically replaced with fresh buffer, and the released amount of laminin and SDF‐1α was quantified using a Micro BCA protein assay kit (Thermo Fisher Scientific, Korea) and a Mouse CXCL12/SDF‐1 alpha Quantikine ELISA kit (R&D Systems). .. mMSCs were cultured in DMEM (Gibco, USA) supplemented with 10% FBS and 1% penicillin–streptomycin at 37 °C in a 5% CO 2 incubator.

    Enzyme-linked Immunosorbent Assay:

    Article Title: A Bioinstructive Injectable Hydrogel for Enhancing Intrinsic Regeneration through Cell Recruitment and Training
    Article Snippet: .. DPBS was periodically replaced with fresh buffer, and the released amount of laminin and SDF‐1α was quantified using a Micro BCA protein assay kit (Thermo Fisher Scientific, Korea) and a Mouse CXCL12/SDF‐1 alpha Quantikine ELISA kit (R&D Systems). .. mMSCs were cultured in DMEM (Gibco, USA) supplemented with 10% FBS and 1% penicillin–streptomycin at 37 °C in a 5% CO 2 incubator.

    Article Title: METTL3-mediated m6A mRNA methylation regulates neutrophil activation through targeting TLR4 signaling.
    Article Snippet: REAGENT or RESOURCE SOURCE IDENTIFIER Antibodies CD90/THY-1 ANTIBODY, PE CONJUG Thermo MA5-17749 Ms NK-1.1 PE PK136 BD Pharmingen 557391 Ms CD45R/B220 PE RA3-6B2 BD Pharmingen 553089 Ms CD117 BV421 2B8 BD Pharmingen 562609 Ms Siglec-F PerCP-Cy5.5 E50-2440 BD Pharmingen 565526 ANTI-M CD115 AFS98 PERCP-EF710 Thermo 46-1152-82 Ms Ly-6G Ly-6C BV510 RB6-8C5 BD Pharmingen 563040 CD11b FITC M1/70 BD Pharmingen 557396 PE/DazzleTM 594 anti-mouse CD184 (CXCR4) Biolegend 146514 BV786 Rat Anti-Mouse CD182 (CXCR2) BD Pharmingen 747811 PE/Cy7 anti-mouse CD182 (CXCR2) Biolegend 149316 Fixable Viability Stain 780 BD Pharmingen 565388 CD34-APC Biolegend 128612 CD16/CD32-Percp-Cy5.5 Biolegend 101324 Mouse CXCR1/IL-8RA PE-conjugated Antibody R&D FAB8628P-100 CD45 Monoclonal Antibody (30-F11), PE, eBioscienceTM Invitrogen 12-0451-82 PerCP/Cyanine5.5 anti-mouse CD45 Antibody Biolegend 103132 PE Rat Anti-Mouse TNF BD 554419 APC Rat Anti-Mouse IL-6 BD 561367 Anti-N6-methyladenosine (m6A) antibody abcam ab232905 Antibody-METTL3 antibody(EPR18810 abcam AB195352 b-Actin (8H10D10) Mouse mAb #3700 CST #3700 Phospho-Myosin Light Chain 2 (Ser19) Mouse mAb #3675 CST #3675 Myosin Light Chain 2 Antibody #3672 CST #3672 PI3 Kinase p110g (D55D5) Rabbit mAb #5405 CST #5405 PI3 Kinase p110a (C73F8) Rabbit mAb #4249 CST #4249 IRAK1 Polyclonal Antibody proteintech 10478-2-AP TIRAP (D6M9Z) Rabbit mAb (Mouse Specific) #13077 CST #13077 CXCR2 Polyclonal Antibody proteintech 20634-1-AP Anti-CXCR4 antibody [EPUMBR3] (ab181020) abcam ab181020 CXCR1 Polyclonal Antibody proteintech 55450-1-AP CXCR1 Polyclonal Antibody proteintech 55450-1-AP TLR4 Monoclonal Antibody proteintech 66350-1-Ig Phospho-p38 MAPK (Thr180/Tyr182) (D3F9) XP Rabbit mAb #4511 CST #4511 Anti-MEK1 + MEK2 antibody [EPR16667] (ab178876) abcam ab178876 Anti-MEK1 (phospho S221) + MEK2 (phospho S221) antibody [MEK12S221-D3] (ab278564) abcam ab278564 TLR4 antibody (76B357.1): sc-52962 Santa Cruz Biotechnology 52962 GRK2 antibody (C-9): sc-13143 Santa Cruz Biotechnology sc-13143 NF-kB p65 Monoclonal antibody proteintech Cat No. 66535-1-Ig Anti-NF-kB p65 antibody [E379] (ab32536) abcam ab32536 Anti-NF-kB p65 (phospho S536) antibody [EP2294Y] (ab76302) abcam ab76302 Phospho-SAPK/JNK (Thr183/Tyr185) (81E11) Rabbit mAb #4668 CST 4668T (Continued on next page) Cell Reports 42, 112259, March 28, 2023 15 .. REAGENT or RESOURCE SOURCE IDENTIFIER GRK5 Polyclonal antibody proteintech Cat No. 17032-1-AP Mouse CXCR2/IL-8RB Antibody R&D MAB2164-100 Chemicals, peptides, and recombinant proteins Recombinant Mouse CXCL1 (KC) (carrier-free) BioLegend 573702 Phalloidin-AF488(Alexa FluorTM 488) Thermo Fisher A12379 Actinomycin D(5mg) APE Xbio A4448 Sodium thioglycolate Sigma-Aldrich T0632-25G Recombinant Mouse CXCL2 (MIP-2) (carrier-free) Biolegend 582502 Recombinant Mouse CXCL1 (KC) (carrier-free) BioLegend 573702 LipofectamineTM 3000 Invitrogen L3000015 Lipopolysaccharide Sigma-Aldrich L2880 Clophosome -A- Clodronate Liposomes (Anionic) FormuMax F70101C-A Critical commercial assays Neutrophil Isolation Kit, mouse Miltenyi Biotec 130-097-658 "Mouse CXCL12/SDF-1 alpha Quantikine ELISA Kit " R&D systems MCX120 ChemoTx#1013 Neuro Probe W193738 EpiQuik CUT&RUN m6A RNA Enrichment (MeRIP) Kit Epigentek A&D Technology Corporation A-P-9018-24 Dual-Luciferase Reporter Assay System (Promega, E1910) Promega, E1910 Promega, E1910 Phorbol 12-myristate 13-acetate (Synonyms: Phorbol myristate acetate; PMA) MCE HY-18739 Mouse TNF alpha Uncoated ELISA Thermo Scientific 88-7324 Mouse IL-6 Uncoated ELISA Thermo Scientific 88-7064 Mouse IL-1 beta Uncoated ELISA Thermo Scientific 88-7013 Mouse CXCL2/MIP-2 Quantikine ELISA Kit R&D systems MM20 Deposited data RNA-seq This paper GSE225143 MeRIP-seq This paper GSE225143 Ribosome-seq This paper GSE225143 Experimental models: Cell lines Human: HL-60 Procell Life Science & Technology N/A Human: 293T/17 Procell Life Science & Technology N/A Experimental models: Organisms/strains CD45.2 C57BL/6mice GemPharmatechM, China N/A CD45.1 C57BL/6mice Ph.D. Zhanghui Chen, Institute of Clinical Medicine, Zhanjiang Central Hospital, Guangdong Medical University, Zhanjiang, China. .. N/A Mettl3flox/flox C57BL/6 mice Chinese Academy of Sciences University N/A Lyzm-Cre C57BL/6 mice Jackson Laboratory N/A C57BL/10ScN mice Jackson Laboratory N/A Oligonucleotides WT-30UTR (TLR4-WT) transcript sequence, see Table S3 This paper N/A MUT-30UTR (TLR4-MUT) transcript sequence, see Table S3 This paper N/A qPCR primers for indicated genes, see Table S1 This paper N/A MeRIP qPCR primers for indicated genes, see Table S2 N/A Recombinant DNA GP-miRGLO plasmids GenePharma Co.,Ltd N/A LV-Tlr4(NM_021297) GeneChem Co.,Ltd 24379-1 (Continued on next page) 16 Cell Reports 42, 112259, March 28, 2023

    Article Title: Endothelial ACKR3 drives atherosclerosis by promoting immune cell adhesion to vascular endothelium
    Article Snippet: Cholesterol and triglyceride levels were quantified in EDTA-plasma samples using enzymatic assays (c.f.a.s. cobas, Roche Diagnostics) according to the manufacturer’s protocol. .. CXCL12 levels in EDTA-plasma samples were measured via commercially available Mouse CXCL12/SDF-1 alpha Quantikine ELISA Kit (R&D Systems), according to the manufacturer’s instructions. .. Phosphorylation of p65 subunit NFkB was quantified via NF kappaB p65 (pS536 + Total) ELISA Kit (Abcam), according to the manufacturer’s instructions.

    Article Title: Neutrophil metalloproteinase driven spleen damage hampers infection control of trypanosomiasis
    Article Snippet: Data was analyzed by BD Accuri TM C6 Plus flow cytometer (BD Biosciences, CA, USA. .. Concentrations of CXCL-12, CXCL-2, S100A8/S100A9, elastase, myeloperoxidase, lipocalin-2, lactoferrin, metalloproteinases MMP-8, MMP-9, MMP-25, TIMP-1, TIMP-2, and BAFF were measured in extracellular spleen homogenates and plasma samples, using the following kits according the manufacturer’s protocols: Mouse CXCL2/MIP-2 Quantikine ELISA Kit (R&D Systems, Minneapolis, MN, USA), Mouse CXCL12/SDF-1 alpha Quantikine ELISA Kit (R&D Systems, Minneapolis, MN, USA), Mouse S100A8/S100A9 Heterodimer DuoSet ELISA (R&D Systems, Minneapolis, MN, USA), Mouse Neutrophil Elastase ELISA Kit (Abcam, Cambridge, UK), Mouse Myeloperoxidase (MPO) ELISA Kit (Abcam, Cambridge, UK), Mouse Lipocalin-2/NGAL DuoSet® ELISA (R&D Systems, Minneapolis, MN, USA), Mouse Lactoferrin (LTF) ELISA Kit (Abbexa Ltd, Cambridge, UK), Mouse in vitro SimpleStep MMP-8 ELISA Kit (Abcam, Cambridge, UK), Mouse MMP-9 ELISA Kit (Abcam, Cambridge, UK), Mouse MMP-25 ELISA Kit (Abbexa Ltd, Cambridge, UK), Mouse TIMP-1 ELISA Kit (Abcam, Cambridge, UK), Mouse TIMP-2 SimpleStep ELISA Kit (Abcam, Cambridge, UK), and Mouse BAFF ELISA Kit (Abcam, Cambridge, UK). .. Mouse spleens were isolated after CO 2 euthanasia of the animals and fixed overnight at 4 °C in neutral buffered 10% formalin solution (Sigma-Aldrich, Missouri, USA).

    Article Title: Neutrophil metalloproteinase driven spleen damage hampers infection control of trypanosomiasis.
    Article Snippet: .. Nature Communications | (2023) 14:5418 12 CXCL2/MIP-2 Quantikine ELISA Kit (R&D Systems, Minneapolis, MN, USA), Mouse CXCL12/SDF-1 alpha Quantikine ELISA Kit (R&D Systems, Minneapolis, MN, USA), Mouse S100A8/S100A9 Heterodimer DuoSet ELISA (R&D Systems, Minneapolis, MN, USA), Mouse Neutrophil Elastase ELISA Kit (Abcam, Cambridge, UK), Mouse Myeloperoxidase (MPO) ELISA Kit (Abcam, Cambridge, UK), Mouse Lipocalin-2/NGAL DuoSet® ELISA (R&D Systems, Minneapolis, MN, USA), Mouse Lactoferrin (LTF) ELISA Kit (Abbexa Ltd, Cambridge, UK), Mouse in vitro SimpleStep MMP-8 ELISA Kit (Abcam, Cambridge, UK), Mouse MMP-9 ELISA Kit (Abcam, Cambridge, UK), MouseMMP-25 ELISA Kit (Abbexa Ltd, Cambridge, UK), Mouse TIMP1 ELISA Kit (Abcam,Cambridge, UK),Mouse TIMP-2 SimpleStep ELISA Kit (Abcam, Cambridge, UK), and Mouse BAFF ELISA Kit (Abcam, Cambridge, UK). ..

    Article Title: Immune checkpoint inhibitor therapy increases systemic SDF-1, cardiac DAMPs Fibronectin-EDA, S100/Calgranulin, galectine-3, and NLRP3-MyD88-chemokine pathways
    Article Snippet: .. Circulating SDF-1 (CXCL-12), IL-1β, IL-6 were quantified in 0,1 mL of plasma through the use of mouse CXCL12/SDF-1 alpha Quantikine ELISA Kit (MCX120, R&D Systems, Minneapolis, MN, USA), mouse IL-1β ELISA kit (BMS6002, Thermo Fisher, Milan, Italy) and mouse IL-6 ELISA kit (KMC0061, Thermo Fisher, Milan, Italy). ..

    Article Title: Bone marrow B cell collapse promotes bone metastasis in breast cancer
    Article Snippet: IL-6 levels were measured with Mouse IL-6 Quantikine ELISA kit (R&D Systems, M6000B). .. CXCL12 levels were measured with the Mouse CXCL12/SDF-1 alpha Quantikine ELISA Kit (R&D Systems, MCX120). .. CCL7/MCP-3 levels were measured with the Mouse MCP-3 Instant ELISATM Kit (Invitrogen, BMS6006INST).

    other:

    Article Title: A Bioinstructive Injectable Hydrogel for Enhancing Intrinsic Regeneration through Cell Recruitment and Training.
    Article Snippet: Measurement of Sizes and Surface Charges: The sizes and zeta potentials of laminin, PP, LS, and PPLS were determined using a Zetasizer Nano ZS (Malvern Instruments Ltd., Worcestershire, UK) at 25 °C.

    Recombinant:

    Article Title: METTL3-mediated m6A mRNA methylation regulates neutrophil activation through targeting TLR4 signaling.
    Article Snippet: REAGENT or RESOURCE SOURCE IDENTIFIER Antibodies CD90/THY-1 ANTIBODY, PE CONJUG Thermo MA5-17749 Ms NK-1.1 PE PK136 BD Pharmingen 557391 Ms CD45R/B220 PE RA3-6B2 BD Pharmingen 553089 Ms CD117 BV421 2B8 BD Pharmingen 562609 Ms Siglec-F PerCP-Cy5.5 E50-2440 BD Pharmingen 565526 ANTI-M CD115 AFS98 PERCP-EF710 Thermo 46-1152-82 Ms Ly-6G Ly-6C BV510 RB6-8C5 BD Pharmingen 563040 CD11b FITC M1/70 BD Pharmingen 557396 PE/DazzleTM 594 anti-mouse CD184 (CXCR4) Biolegend 146514 BV786 Rat Anti-Mouse CD182 (CXCR2) BD Pharmingen 747811 PE/Cy7 anti-mouse CD182 (CXCR2) Biolegend 149316 Fixable Viability Stain 780 BD Pharmingen 565388 CD34-APC Biolegend 128612 CD16/CD32-Percp-Cy5.5 Biolegend 101324 Mouse CXCR1/IL-8RA PE-conjugated Antibody R&D FAB8628P-100 CD45 Monoclonal Antibody (30-F11), PE, eBioscienceTM Invitrogen 12-0451-82 PerCP/Cyanine5.5 anti-mouse CD45 Antibody Biolegend 103132 PE Rat Anti-Mouse TNF BD 554419 APC Rat Anti-Mouse IL-6 BD 561367 Anti-N6-methyladenosine (m6A) antibody abcam ab232905 Antibody-METTL3 antibody(EPR18810 abcam AB195352 b-Actin (8H10D10) Mouse mAb #3700 CST #3700 Phospho-Myosin Light Chain 2 (Ser19) Mouse mAb #3675 CST #3675 Myosin Light Chain 2 Antibody #3672 CST #3672 PI3 Kinase p110g (D55D5) Rabbit mAb #5405 CST #5405 PI3 Kinase p110a (C73F8) Rabbit mAb #4249 CST #4249 IRAK1 Polyclonal Antibody proteintech 10478-2-AP TIRAP (D6M9Z) Rabbit mAb (Mouse Specific) #13077 CST #13077 CXCR2 Polyclonal Antibody proteintech 20634-1-AP Anti-CXCR4 antibody [EPUMBR3] (ab181020) abcam ab181020 CXCR1 Polyclonal Antibody proteintech 55450-1-AP CXCR1 Polyclonal Antibody proteintech 55450-1-AP TLR4 Monoclonal Antibody proteintech 66350-1-Ig Phospho-p38 MAPK (Thr180/Tyr182) (D3F9) XP Rabbit mAb #4511 CST #4511 Anti-MEK1 + MEK2 antibody [EPR16667] (ab178876) abcam ab178876 Anti-MEK1 (phospho S221) + MEK2 (phospho S221) antibody [MEK12S221-D3] (ab278564) abcam ab278564 TLR4 antibody (76B357.1): sc-52962 Santa Cruz Biotechnology 52962 GRK2 antibody (C-9): sc-13143 Santa Cruz Biotechnology sc-13143 NF-kB p65 Monoclonal antibody proteintech Cat No. 66535-1-Ig Anti-NF-kB p65 antibody [E379] (ab32536) abcam ab32536 Anti-NF-kB p65 (phospho S536) antibody [EP2294Y] (ab76302) abcam ab76302 Phospho-SAPK/JNK (Thr183/Tyr185) (81E11) Rabbit mAb #4668 CST 4668T (Continued on next page) Cell Reports 42, 112259, March 28, 2023 15 .. REAGENT or RESOURCE SOURCE IDENTIFIER GRK5 Polyclonal antibody proteintech Cat No. 17032-1-AP Mouse CXCR2/IL-8RB Antibody R&D MAB2164-100 Chemicals, peptides, and recombinant proteins Recombinant Mouse CXCL1 (KC) (carrier-free) BioLegend 573702 Phalloidin-AF488(Alexa FluorTM 488) Thermo Fisher A12379 Actinomycin D(5mg) APE Xbio A4448 Sodium thioglycolate Sigma-Aldrich T0632-25G Recombinant Mouse CXCL2 (MIP-2) (carrier-free) Biolegend 582502 Recombinant Mouse CXCL1 (KC) (carrier-free) BioLegend 573702 LipofectamineTM 3000 Invitrogen L3000015 Lipopolysaccharide Sigma-Aldrich L2880 Clophosome -A- Clodronate Liposomes (Anionic) FormuMax F70101C-A Critical commercial assays Neutrophil Isolation Kit, mouse Miltenyi Biotec 130-097-658 "Mouse CXCL12/SDF-1 alpha Quantikine ELISA Kit " R&D systems MCX120 ChemoTx#1013 Neuro Probe W193738 EpiQuik CUT&RUN m6A RNA Enrichment (MeRIP) Kit Epigentek A&D Technology Corporation A-P-9018-24 Dual-Luciferase Reporter Assay System (Promega, E1910) Promega, E1910 Promega, E1910 Phorbol 12-myristate 13-acetate (Synonyms: Phorbol myristate acetate; PMA) MCE HY-18739 Mouse TNF alpha Uncoated ELISA Thermo Scientific 88-7324 Mouse IL-6 Uncoated ELISA Thermo Scientific 88-7064 Mouse IL-1 beta Uncoated ELISA Thermo Scientific 88-7013 Mouse CXCL2/MIP-2 Quantikine ELISA Kit R&D systems MM20 Deposited data RNA-seq This paper GSE225143 MeRIP-seq This paper GSE225143 Ribosome-seq This paper GSE225143 Experimental models: Cell lines Human: HL-60 Procell Life Science & Technology N/A Human: 293T/17 Procell Life Science & Technology N/A Experimental models: Organisms/strains CD45.2 C57BL/6mice GemPharmatechM, China N/A CD45.1 C57BL/6mice Ph.D. Zhanghui Chen, Institute of Clinical Medicine, Zhanjiang Central Hospital, Guangdong Medical University, Zhanjiang, China. .. N/A Mettl3flox/flox C57BL/6 mice Chinese Academy of Sciences University N/A Lyzm-Cre C57BL/6 mice Jackson Laboratory N/A C57BL/10ScN mice Jackson Laboratory N/A Oligonucleotides WT-30UTR (TLR4-WT) transcript sequence, see Table S3 This paper N/A MUT-30UTR (TLR4-MUT) transcript sequence, see Table S3 This paper N/A qPCR primers for indicated genes, see Table S1 This paper N/A MeRIP qPCR primers for indicated genes, see Table S2 N/A Recombinant DNA GP-miRGLO plasmids GenePharma Co.,Ltd N/A LV-Tlr4(NM_021297) GeneChem Co.,Ltd 24379-1 (Continued on next page) 16 Cell Reports 42, 112259, March 28, 2023

    Liposomes:

    Article Title: METTL3-mediated m6A mRNA methylation regulates neutrophil activation through targeting TLR4 signaling.
    Article Snippet: REAGENT or RESOURCE SOURCE IDENTIFIER Antibodies CD90/THY-1 ANTIBODY, PE CONJUG Thermo MA5-17749 Ms NK-1.1 PE PK136 BD Pharmingen 557391 Ms CD45R/B220 PE RA3-6B2 BD Pharmingen 553089 Ms CD117 BV421 2B8 BD Pharmingen 562609 Ms Siglec-F PerCP-Cy5.5 E50-2440 BD Pharmingen 565526 ANTI-M CD115 AFS98 PERCP-EF710 Thermo 46-1152-82 Ms Ly-6G Ly-6C BV510 RB6-8C5 BD Pharmingen 563040 CD11b FITC M1/70 BD Pharmingen 557396 PE/DazzleTM 594 anti-mouse CD184 (CXCR4) Biolegend 146514 BV786 Rat Anti-Mouse CD182 (CXCR2) BD Pharmingen 747811 PE/Cy7 anti-mouse CD182 (CXCR2) Biolegend 149316 Fixable Viability Stain 780 BD Pharmingen 565388 CD34-APC Biolegend 128612 CD16/CD32-Percp-Cy5.5 Biolegend 101324 Mouse CXCR1/IL-8RA PE-conjugated Antibody R&D FAB8628P-100 CD45 Monoclonal Antibody (30-F11), PE, eBioscienceTM Invitrogen 12-0451-82 PerCP/Cyanine5.5 anti-mouse CD45 Antibody Biolegend 103132 PE Rat Anti-Mouse TNF BD 554419 APC Rat Anti-Mouse IL-6 BD 561367 Anti-N6-methyladenosine (m6A) antibody abcam ab232905 Antibody-METTL3 antibody(EPR18810 abcam AB195352 b-Actin (8H10D10) Mouse mAb #3700 CST #3700 Phospho-Myosin Light Chain 2 (Ser19) Mouse mAb #3675 CST #3675 Myosin Light Chain 2 Antibody #3672 CST #3672 PI3 Kinase p110g (D55D5) Rabbit mAb #5405 CST #5405 PI3 Kinase p110a (C73F8) Rabbit mAb #4249 CST #4249 IRAK1 Polyclonal Antibody proteintech 10478-2-AP TIRAP (D6M9Z) Rabbit mAb (Mouse Specific) #13077 CST #13077 CXCR2 Polyclonal Antibody proteintech 20634-1-AP Anti-CXCR4 antibody [EPUMBR3] (ab181020) abcam ab181020 CXCR1 Polyclonal Antibody proteintech 55450-1-AP CXCR1 Polyclonal Antibody proteintech 55450-1-AP TLR4 Monoclonal Antibody proteintech 66350-1-Ig Phospho-p38 MAPK (Thr180/Tyr182) (D3F9) XP Rabbit mAb #4511 CST #4511 Anti-MEK1 + MEK2 antibody [EPR16667] (ab178876) abcam ab178876 Anti-MEK1 (phospho S221) + MEK2 (phospho S221) antibody [MEK12S221-D3] (ab278564) abcam ab278564 TLR4 antibody (76B357.1): sc-52962 Santa Cruz Biotechnology 52962 GRK2 antibody (C-9): sc-13143 Santa Cruz Biotechnology sc-13143 NF-kB p65 Monoclonal antibody proteintech Cat No. 66535-1-Ig Anti-NF-kB p65 antibody [E379] (ab32536) abcam ab32536 Anti-NF-kB p65 (phospho S536) antibody [EP2294Y] (ab76302) abcam ab76302 Phospho-SAPK/JNK (Thr183/Tyr185) (81E11) Rabbit mAb #4668 CST 4668T (Continued on next page) Cell Reports 42, 112259, March 28, 2023 15 .. REAGENT or RESOURCE SOURCE IDENTIFIER GRK5 Polyclonal antibody proteintech Cat No. 17032-1-AP Mouse CXCR2/IL-8RB Antibody R&D MAB2164-100 Chemicals, peptides, and recombinant proteins Recombinant Mouse CXCL1 (KC) (carrier-free) BioLegend 573702 Phalloidin-AF488(Alexa FluorTM 488) Thermo Fisher A12379 Actinomycin D(5mg) APE Xbio A4448 Sodium thioglycolate Sigma-Aldrich T0632-25G Recombinant Mouse CXCL2 (MIP-2) (carrier-free) Biolegend 582502 Recombinant Mouse CXCL1 (KC) (carrier-free) BioLegend 573702 LipofectamineTM 3000 Invitrogen L3000015 Lipopolysaccharide Sigma-Aldrich L2880 Clophosome -A- Clodronate Liposomes (Anionic) FormuMax F70101C-A Critical commercial assays Neutrophil Isolation Kit, mouse Miltenyi Biotec 130-097-658 "Mouse CXCL12/SDF-1 alpha Quantikine ELISA Kit " R&D systems MCX120 ChemoTx#1013 Neuro Probe W193738 EpiQuik CUT&RUN m6A RNA Enrichment (MeRIP) Kit Epigentek A&D Technology Corporation A-P-9018-24 Dual-Luciferase Reporter Assay System (Promega, E1910) Promega, E1910 Promega, E1910 Phorbol 12-myristate 13-acetate (Synonyms: Phorbol myristate acetate; PMA) MCE HY-18739 Mouse TNF alpha Uncoated ELISA Thermo Scientific 88-7324 Mouse IL-6 Uncoated ELISA Thermo Scientific 88-7064 Mouse IL-1 beta Uncoated ELISA Thermo Scientific 88-7013 Mouse CXCL2/MIP-2 Quantikine ELISA Kit R&D systems MM20 Deposited data RNA-seq This paper GSE225143 MeRIP-seq This paper GSE225143 Ribosome-seq This paper GSE225143 Experimental models: Cell lines Human: HL-60 Procell Life Science & Technology N/A Human: 293T/17 Procell Life Science & Technology N/A Experimental models: Organisms/strains CD45.2 C57BL/6mice GemPharmatechM, China N/A CD45.1 C57BL/6mice Ph.D. Zhanghui Chen, Institute of Clinical Medicine, Zhanjiang Central Hospital, Guangdong Medical University, Zhanjiang, China. .. N/A Mettl3flox/flox C57BL/6 mice Chinese Academy of Sciences University N/A Lyzm-Cre C57BL/6 mice Jackson Laboratory N/A C57BL/10ScN mice Jackson Laboratory N/A Oligonucleotides WT-30UTR (TLR4-WT) transcript sequence, see Table S3 This paper N/A MUT-30UTR (TLR4-MUT) transcript sequence, see Table S3 This paper N/A qPCR primers for indicated genes, see Table S1 This paper N/A MeRIP qPCR primers for indicated genes, see Table S2 N/A Recombinant DNA GP-miRGLO plasmids GenePharma Co.,Ltd N/A LV-Tlr4(NM_021297) GeneChem Co.,Ltd 24379-1 (Continued on next page) 16 Cell Reports 42, 112259, March 28, 2023

    Isolation:

    Article Title: METTL3-mediated m6A mRNA methylation regulates neutrophil activation through targeting TLR4 signaling.
    Article Snippet: REAGENT or RESOURCE SOURCE IDENTIFIER Antibodies CD90/THY-1 ANTIBODY, PE CONJUG Thermo MA5-17749 Ms NK-1.1 PE PK136 BD Pharmingen 557391 Ms CD45R/B220 PE RA3-6B2 BD Pharmingen 553089 Ms CD117 BV421 2B8 BD Pharmingen 562609 Ms Siglec-F PerCP-Cy5.5 E50-2440 BD Pharmingen 565526 ANTI-M CD115 AFS98 PERCP-EF710 Thermo 46-1152-82 Ms Ly-6G Ly-6C BV510 RB6-8C5 BD Pharmingen 563040 CD11b FITC M1/70 BD Pharmingen 557396 PE/DazzleTM 594 anti-mouse CD184 (CXCR4) Biolegend 146514 BV786 Rat Anti-Mouse CD182 (CXCR2) BD Pharmingen 747811 PE/Cy7 anti-mouse CD182 (CXCR2) Biolegend 149316 Fixable Viability Stain 780 BD Pharmingen 565388 CD34-APC Biolegend 128612 CD16/CD32-Percp-Cy5.5 Biolegend 101324 Mouse CXCR1/IL-8RA PE-conjugated Antibody R&D FAB8628P-100 CD45 Monoclonal Antibody (30-F11), PE, eBioscienceTM Invitrogen 12-0451-82 PerCP/Cyanine5.5 anti-mouse CD45 Antibody Biolegend 103132 PE Rat Anti-Mouse TNF BD 554419 APC Rat Anti-Mouse IL-6 BD 561367 Anti-N6-methyladenosine (m6A) antibody abcam ab232905 Antibody-METTL3 antibody(EPR18810 abcam AB195352 b-Actin (8H10D10) Mouse mAb #3700 CST #3700 Phospho-Myosin Light Chain 2 (Ser19) Mouse mAb #3675 CST #3675 Myosin Light Chain 2 Antibody #3672 CST #3672 PI3 Kinase p110g (D55D5) Rabbit mAb #5405 CST #5405 PI3 Kinase p110a (C73F8) Rabbit mAb #4249 CST #4249 IRAK1 Polyclonal Antibody proteintech 10478-2-AP TIRAP (D6M9Z) Rabbit mAb (Mouse Specific) #13077 CST #13077 CXCR2 Polyclonal Antibody proteintech 20634-1-AP Anti-CXCR4 antibody [EPUMBR3] (ab181020) abcam ab181020 CXCR1 Polyclonal Antibody proteintech 55450-1-AP CXCR1 Polyclonal Antibody proteintech 55450-1-AP TLR4 Monoclonal Antibody proteintech 66350-1-Ig Phospho-p38 MAPK (Thr180/Tyr182) (D3F9) XP Rabbit mAb #4511 CST #4511 Anti-MEK1 + MEK2 antibody [EPR16667] (ab178876) abcam ab178876 Anti-MEK1 (phospho S221) + MEK2 (phospho S221) antibody [MEK12S221-D3] (ab278564) abcam ab278564 TLR4 antibody (76B357.1): sc-52962 Santa Cruz Biotechnology 52962 GRK2 antibody (C-9): sc-13143 Santa Cruz Biotechnology sc-13143 NF-kB p65 Monoclonal antibody proteintech Cat No. 66535-1-Ig Anti-NF-kB p65 antibody [E379] (ab32536) abcam ab32536 Anti-NF-kB p65 (phospho S536) antibody [EP2294Y] (ab76302) abcam ab76302 Phospho-SAPK/JNK (Thr183/Tyr185) (81E11) Rabbit mAb #4668 CST 4668T (Continued on next page) Cell Reports 42, 112259, March 28, 2023 15 .. REAGENT or RESOURCE SOURCE IDENTIFIER GRK5 Polyclonal antibody proteintech Cat No. 17032-1-AP Mouse CXCR2/IL-8RB Antibody R&D MAB2164-100 Chemicals, peptides, and recombinant proteins Recombinant Mouse CXCL1 (KC) (carrier-free) BioLegend 573702 Phalloidin-AF488(Alexa FluorTM 488) Thermo Fisher A12379 Actinomycin D(5mg) APE Xbio A4448 Sodium thioglycolate Sigma-Aldrich T0632-25G Recombinant Mouse CXCL2 (MIP-2) (carrier-free) Biolegend 582502 Recombinant Mouse CXCL1 (KC) (carrier-free) BioLegend 573702 LipofectamineTM 3000 Invitrogen L3000015 Lipopolysaccharide Sigma-Aldrich L2880 Clophosome -A- Clodronate Liposomes (Anionic) FormuMax F70101C-A Critical commercial assays Neutrophil Isolation Kit, mouse Miltenyi Biotec 130-097-658 "Mouse CXCL12/SDF-1 alpha Quantikine ELISA Kit " R&D systems MCX120 ChemoTx#1013 Neuro Probe W193738 EpiQuik CUT&RUN m6A RNA Enrichment (MeRIP) Kit Epigentek A&D Technology Corporation A-P-9018-24 Dual-Luciferase Reporter Assay System (Promega, E1910) Promega, E1910 Promega, E1910 Phorbol 12-myristate 13-acetate (Synonyms: Phorbol myristate acetate; PMA) MCE HY-18739 Mouse TNF alpha Uncoated ELISA Thermo Scientific 88-7324 Mouse IL-6 Uncoated ELISA Thermo Scientific 88-7064 Mouse IL-1 beta Uncoated ELISA Thermo Scientific 88-7013 Mouse CXCL2/MIP-2 Quantikine ELISA Kit R&D systems MM20 Deposited data RNA-seq This paper GSE225143 MeRIP-seq This paper GSE225143 Ribosome-seq This paper GSE225143 Experimental models: Cell lines Human: HL-60 Procell Life Science & Technology N/A Human: 293T/17 Procell Life Science & Technology N/A Experimental models: Organisms/strains CD45.2 C57BL/6mice GemPharmatechM, China N/A CD45.1 C57BL/6mice Ph.D. Zhanghui Chen, Institute of Clinical Medicine, Zhanjiang Central Hospital, Guangdong Medical University, Zhanjiang, China. .. N/A Mettl3flox/flox C57BL/6 mice Chinese Academy of Sciences University N/A Lyzm-Cre C57BL/6 mice Jackson Laboratory N/A C57BL/10ScN mice Jackson Laboratory N/A Oligonucleotides WT-30UTR (TLR4-WT) transcript sequence, see Table S3 This paper N/A MUT-30UTR (TLR4-MUT) transcript sequence, see Table S3 This paper N/A qPCR primers for indicated genes, see Table S1 This paper N/A MeRIP qPCR primers for indicated genes, see Table S2 N/A Recombinant DNA GP-miRGLO plasmids GenePharma Co.,Ltd N/A LV-Tlr4(NM_021297) GeneChem Co.,Ltd 24379-1 (Continued on next page) 16 Cell Reports 42, 112259, March 28, 2023

    Reporter Assay:

    Article Title: METTL3-mediated m6A mRNA methylation regulates neutrophil activation through targeting TLR4 signaling.
    Article Snippet: REAGENT or RESOURCE SOURCE IDENTIFIER Antibodies CD90/THY-1 ANTIBODY, PE CONJUG Thermo MA5-17749 Ms NK-1.1 PE PK136 BD Pharmingen 557391 Ms CD45R/B220 PE RA3-6B2 BD Pharmingen 553089 Ms CD117 BV421 2B8 BD Pharmingen 562609 Ms Siglec-F PerCP-Cy5.5 E50-2440 BD Pharmingen 565526 ANTI-M CD115 AFS98 PERCP-EF710 Thermo 46-1152-82 Ms Ly-6G Ly-6C BV510 RB6-8C5 BD Pharmingen 563040 CD11b FITC M1/70 BD Pharmingen 557396 PE/DazzleTM 594 anti-mouse CD184 (CXCR4) Biolegend 146514 BV786 Rat Anti-Mouse CD182 (CXCR2) BD Pharmingen 747811 PE/Cy7 anti-mouse CD182 (CXCR2) Biolegend 149316 Fixable Viability Stain 780 BD Pharmingen 565388 CD34-APC Biolegend 128612 CD16/CD32-Percp-Cy5.5 Biolegend 101324 Mouse CXCR1/IL-8RA PE-conjugated Antibody R&D FAB8628P-100 CD45 Monoclonal Antibody (30-F11), PE, eBioscienceTM Invitrogen 12-0451-82 PerCP/Cyanine5.5 anti-mouse CD45 Antibody Biolegend 103132 PE Rat Anti-Mouse TNF BD 554419 APC Rat Anti-Mouse IL-6 BD 561367 Anti-N6-methyladenosine (m6A) antibody abcam ab232905 Antibody-METTL3 antibody(EPR18810 abcam AB195352 b-Actin (8H10D10) Mouse mAb #3700 CST #3700 Phospho-Myosin Light Chain 2 (Ser19) Mouse mAb #3675 CST #3675 Myosin Light Chain 2 Antibody #3672 CST #3672 PI3 Kinase p110g (D55D5) Rabbit mAb #5405 CST #5405 PI3 Kinase p110a (C73F8) Rabbit mAb #4249 CST #4249 IRAK1 Polyclonal Antibody proteintech 10478-2-AP TIRAP (D6M9Z) Rabbit mAb (Mouse Specific) #13077 CST #13077 CXCR2 Polyclonal Antibody proteintech 20634-1-AP Anti-CXCR4 antibody [EPUMBR3] (ab181020) abcam ab181020 CXCR1 Polyclonal Antibody proteintech 55450-1-AP CXCR1 Polyclonal Antibody proteintech 55450-1-AP TLR4 Monoclonal Antibody proteintech 66350-1-Ig Phospho-p38 MAPK (Thr180/Tyr182) (D3F9) XP Rabbit mAb #4511 CST #4511 Anti-MEK1 + MEK2 antibody [EPR16667] (ab178876) abcam ab178876 Anti-MEK1 (phospho S221) + MEK2 (phospho S221) antibody [MEK12S221-D3] (ab278564) abcam ab278564 TLR4 antibody (76B357.1): sc-52962 Santa Cruz Biotechnology 52962 GRK2 antibody (C-9): sc-13143 Santa Cruz Biotechnology sc-13143 NF-kB p65 Monoclonal antibody proteintech Cat No. 66535-1-Ig Anti-NF-kB p65 antibody [E379] (ab32536) abcam ab32536 Anti-NF-kB p65 (phospho S536) antibody [EP2294Y] (ab76302) abcam ab76302 Phospho-SAPK/JNK (Thr183/Tyr185) (81E11) Rabbit mAb #4668 CST 4668T (Continued on next page) Cell Reports 42, 112259, March 28, 2023 15 .. REAGENT or RESOURCE SOURCE IDENTIFIER GRK5 Polyclonal antibody proteintech Cat No. 17032-1-AP Mouse CXCR2/IL-8RB Antibody R&D MAB2164-100 Chemicals, peptides, and recombinant proteins Recombinant Mouse CXCL1 (KC) (carrier-free) BioLegend 573702 Phalloidin-AF488(Alexa FluorTM 488) Thermo Fisher A12379 Actinomycin D(5mg) APE Xbio A4448 Sodium thioglycolate Sigma-Aldrich T0632-25G Recombinant Mouse CXCL2 (MIP-2) (carrier-free) Biolegend 582502 Recombinant Mouse CXCL1 (KC) (carrier-free) BioLegend 573702 LipofectamineTM 3000 Invitrogen L3000015 Lipopolysaccharide Sigma-Aldrich L2880 Clophosome -A- Clodronate Liposomes (Anionic) FormuMax F70101C-A Critical commercial assays Neutrophil Isolation Kit, mouse Miltenyi Biotec 130-097-658 "Mouse CXCL12/SDF-1 alpha Quantikine ELISA Kit " R&D systems MCX120 ChemoTx#1013 Neuro Probe W193738 EpiQuik CUT&RUN m6A RNA Enrichment (MeRIP) Kit Epigentek A&D Technology Corporation A-P-9018-24 Dual-Luciferase Reporter Assay System (Promega, E1910) Promega, E1910 Promega, E1910 Phorbol 12-myristate 13-acetate (Synonyms: Phorbol myristate acetate; PMA) MCE HY-18739 Mouse TNF alpha Uncoated ELISA Thermo Scientific 88-7324 Mouse IL-6 Uncoated ELISA Thermo Scientific 88-7064 Mouse IL-1 beta Uncoated ELISA Thermo Scientific 88-7013 Mouse CXCL2/MIP-2 Quantikine ELISA Kit R&D systems MM20 Deposited data RNA-seq This paper GSE225143 MeRIP-seq This paper GSE225143 Ribosome-seq This paper GSE225143 Experimental models: Cell lines Human: HL-60 Procell Life Science & Technology N/A Human: 293T/17 Procell Life Science & Technology N/A Experimental models: Organisms/strains CD45.2 C57BL/6mice GemPharmatechM, China N/A CD45.1 C57BL/6mice Ph.D. Zhanghui Chen, Institute of Clinical Medicine, Zhanjiang Central Hospital, Guangdong Medical University, Zhanjiang, China. .. N/A Mettl3flox/flox C57BL/6 mice Chinese Academy of Sciences University N/A Lyzm-Cre C57BL/6 mice Jackson Laboratory N/A C57BL/10ScN mice Jackson Laboratory N/A Oligonucleotides WT-30UTR (TLR4-WT) transcript sequence, see Table S3 This paper N/A MUT-30UTR (TLR4-MUT) transcript sequence, see Table S3 This paper N/A qPCR primers for indicated genes, see Table S1 This paper N/A MeRIP qPCR primers for indicated genes, see Table S2 N/A Recombinant DNA GP-miRGLO plasmids GenePharma Co.,Ltd N/A LV-Tlr4(NM_021297) GeneChem Co.,Ltd 24379-1 (Continued on next page) 16 Cell Reports 42, 112259, March 28, 2023

    RNA Sequencing:

    Article Title: METTL3-mediated m6A mRNA methylation regulates neutrophil activation through targeting TLR4 signaling.
    Article Snippet: REAGENT or RESOURCE SOURCE IDENTIFIER Antibodies CD90/THY-1 ANTIBODY, PE CONJUG Thermo MA5-17749 Ms NK-1.1 PE PK136 BD Pharmingen 557391 Ms CD45R/B220 PE RA3-6B2 BD Pharmingen 553089 Ms CD117 BV421 2B8 BD Pharmingen 562609 Ms Siglec-F PerCP-Cy5.5 E50-2440 BD Pharmingen 565526 ANTI-M CD115 AFS98 PERCP-EF710 Thermo 46-1152-82 Ms Ly-6G Ly-6C BV510 RB6-8C5 BD Pharmingen 563040 CD11b FITC M1/70 BD Pharmingen 557396 PE/DazzleTM 594 anti-mouse CD184 (CXCR4) Biolegend 146514 BV786 Rat Anti-Mouse CD182 (CXCR2) BD Pharmingen 747811 PE/Cy7 anti-mouse CD182 (CXCR2) Biolegend 149316 Fixable Viability Stain 780 BD Pharmingen 565388 CD34-APC Biolegend 128612 CD16/CD32-Percp-Cy5.5 Biolegend 101324 Mouse CXCR1/IL-8RA PE-conjugated Antibody R&D FAB8628P-100 CD45 Monoclonal Antibody (30-F11), PE, eBioscienceTM Invitrogen 12-0451-82 PerCP/Cyanine5.5 anti-mouse CD45 Antibody Biolegend 103132 PE Rat Anti-Mouse TNF BD 554419 APC Rat Anti-Mouse IL-6 BD 561367 Anti-N6-methyladenosine (m6A) antibody abcam ab232905 Antibody-METTL3 antibody(EPR18810 abcam AB195352 b-Actin (8H10D10) Mouse mAb #3700 CST #3700 Phospho-Myosin Light Chain 2 (Ser19) Mouse mAb #3675 CST #3675 Myosin Light Chain 2 Antibody #3672 CST #3672 PI3 Kinase p110g (D55D5) Rabbit mAb #5405 CST #5405 PI3 Kinase p110a (C73F8) Rabbit mAb #4249 CST #4249 IRAK1 Polyclonal Antibody proteintech 10478-2-AP TIRAP (D6M9Z) Rabbit mAb (Mouse Specific) #13077 CST #13077 CXCR2 Polyclonal Antibody proteintech 20634-1-AP Anti-CXCR4 antibody [EPUMBR3] (ab181020) abcam ab181020 CXCR1 Polyclonal Antibody proteintech 55450-1-AP CXCR1 Polyclonal Antibody proteintech 55450-1-AP TLR4 Monoclonal Antibody proteintech 66350-1-Ig Phospho-p38 MAPK (Thr180/Tyr182) (D3F9) XP Rabbit mAb #4511 CST #4511 Anti-MEK1 + MEK2 antibody [EPR16667] (ab178876) abcam ab178876 Anti-MEK1 (phospho S221) + MEK2 (phospho S221) antibody [MEK12S221-D3] (ab278564) abcam ab278564 TLR4 antibody (76B357.1): sc-52962 Santa Cruz Biotechnology 52962 GRK2 antibody (C-9): sc-13143 Santa Cruz Biotechnology sc-13143 NF-kB p65 Monoclonal antibody proteintech Cat No. 66535-1-Ig Anti-NF-kB p65 antibody [E379] (ab32536) abcam ab32536 Anti-NF-kB p65 (phospho S536) antibody [EP2294Y] (ab76302) abcam ab76302 Phospho-SAPK/JNK (Thr183/Tyr185) (81E11) Rabbit mAb #4668 CST 4668T (Continued on next page) Cell Reports 42, 112259, March 28, 2023 15 .. REAGENT or RESOURCE SOURCE IDENTIFIER GRK5 Polyclonal antibody proteintech Cat No. 17032-1-AP Mouse CXCR2/IL-8RB Antibody R&D MAB2164-100 Chemicals, peptides, and recombinant proteins Recombinant Mouse CXCL1 (KC) (carrier-free) BioLegend 573702 Phalloidin-AF488(Alexa FluorTM 488) Thermo Fisher A12379 Actinomycin D(5mg) APE Xbio A4448 Sodium thioglycolate Sigma-Aldrich T0632-25G Recombinant Mouse CXCL2 (MIP-2) (carrier-free) Biolegend 582502 Recombinant Mouse CXCL1 (KC) (carrier-free) BioLegend 573702 LipofectamineTM 3000 Invitrogen L3000015 Lipopolysaccharide Sigma-Aldrich L2880 Clophosome -A- Clodronate Liposomes (Anionic) FormuMax F70101C-A Critical commercial assays Neutrophil Isolation Kit, mouse Miltenyi Biotec 130-097-658 "Mouse CXCL12/SDF-1 alpha Quantikine ELISA Kit " R&D systems MCX120 ChemoTx#1013 Neuro Probe W193738 EpiQuik CUT&RUN m6A RNA Enrichment (MeRIP) Kit Epigentek A&D Technology Corporation A-P-9018-24 Dual-Luciferase Reporter Assay System (Promega, E1910) Promega, E1910 Promega, E1910 Phorbol 12-myristate 13-acetate (Synonyms: Phorbol myristate acetate; PMA) MCE HY-18739 Mouse TNF alpha Uncoated ELISA Thermo Scientific 88-7324 Mouse IL-6 Uncoated ELISA Thermo Scientific 88-7064 Mouse IL-1 beta Uncoated ELISA Thermo Scientific 88-7013 Mouse CXCL2/MIP-2 Quantikine ELISA Kit R&D systems MM20 Deposited data RNA-seq This paper GSE225143 MeRIP-seq This paper GSE225143 Ribosome-seq This paper GSE225143 Experimental models: Cell lines Human: HL-60 Procell Life Science & Technology N/A Human: 293T/17 Procell Life Science & Technology N/A Experimental models: Organisms/strains CD45.2 C57BL/6mice GemPharmatechM, China N/A CD45.1 C57BL/6mice Ph.D. Zhanghui Chen, Institute of Clinical Medicine, Zhanjiang Central Hospital, Guangdong Medical University, Zhanjiang, China. .. N/A Mettl3flox/flox C57BL/6 mice Chinese Academy of Sciences University N/A Lyzm-Cre C57BL/6 mice Jackson Laboratory N/A C57BL/10ScN mice Jackson Laboratory N/A Oligonucleotides WT-30UTR (TLR4-WT) transcript sequence, see Table S3 This paper N/A MUT-30UTR (TLR4-MUT) transcript sequence, see Table S3 This paper N/A qPCR primers for indicated genes, see Table S1 This paper N/A MeRIP qPCR primers for indicated genes, see Table S2 N/A Recombinant DNA GP-miRGLO plasmids GenePharma Co.,Ltd N/A LV-Tlr4(NM_021297) GeneChem Co.,Ltd 24379-1 (Continued on next page) 16 Cell Reports 42, 112259, March 28, 2023

    Clinical Proteomics:

    Article Title: Neutrophil metalloproteinase driven spleen damage hampers infection control of trypanosomiasis
    Article Snippet: Data was analyzed by BD Accuri TM C6 Plus flow cytometer (BD Biosciences, CA, USA. .. Concentrations of CXCL-12, CXCL-2, S100A8/S100A9, elastase, myeloperoxidase, lipocalin-2, lactoferrin, metalloproteinases MMP-8, MMP-9, MMP-25, TIMP-1, TIMP-2, and BAFF were measured in extracellular spleen homogenates and plasma samples, using the following kits according the manufacturer’s protocols: Mouse CXCL2/MIP-2 Quantikine ELISA Kit (R&D Systems, Minneapolis, MN, USA), Mouse CXCL12/SDF-1 alpha Quantikine ELISA Kit (R&D Systems, Minneapolis, MN, USA), Mouse S100A8/S100A9 Heterodimer DuoSet ELISA (R&D Systems, Minneapolis, MN, USA), Mouse Neutrophil Elastase ELISA Kit (Abcam, Cambridge, UK), Mouse Myeloperoxidase (MPO) ELISA Kit (Abcam, Cambridge, UK), Mouse Lipocalin-2/NGAL DuoSet® ELISA (R&D Systems, Minneapolis, MN, USA), Mouse Lactoferrin (LTF) ELISA Kit (Abbexa Ltd, Cambridge, UK), Mouse in vitro SimpleStep MMP-8 ELISA Kit (Abcam, Cambridge, UK), Mouse MMP-9 ELISA Kit (Abcam, Cambridge, UK), Mouse MMP-25 ELISA Kit (Abbexa Ltd, Cambridge, UK), Mouse TIMP-1 ELISA Kit (Abcam, Cambridge, UK), Mouse TIMP-2 SimpleStep ELISA Kit (Abcam, Cambridge, UK), and Mouse BAFF ELISA Kit (Abcam, Cambridge, UK). .. Mouse spleens were isolated after CO 2 euthanasia of the animals and fixed overnight at 4 °C in neutral buffered 10% formalin solution (Sigma-Aldrich, Missouri, USA).

    Article Title: Immune checkpoint inhibitor therapy increases systemic SDF-1, cardiac DAMPs Fibronectin-EDA, S100/Calgranulin, galectine-3, and NLRP3-MyD88-chemokine pathways
    Article Snippet: .. Circulating SDF-1 (CXCL-12), IL-1β, IL-6 were quantified in 0,1 mL of plasma through the use of mouse CXCL12/SDF-1 alpha Quantikine ELISA Kit (MCX120, R&D Systems, Minneapolis, MN, USA), mouse IL-1β ELISA kit (BMS6002, Thermo Fisher, Milan, Italy) and mouse IL-6 ELISA kit (KMC0061, Thermo Fisher, Milan, Italy). ..

    In Vitro:

    Article Title: Neutrophil metalloproteinase driven spleen damage hampers infection control of trypanosomiasis
    Article Snippet: Data was analyzed by BD Accuri TM C6 Plus flow cytometer (BD Biosciences, CA, USA. .. Concentrations of CXCL-12, CXCL-2, S100A8/S100A9, elastase, myeloperoxidase, lipocalin-2, lactoferrin, metalloproteinases MMP-8, MMP-9, MMP-25, TIMP-1, TIMP-2, and BAFF were measured in extracellular spleen homogenates and plasma samples, using the following kits according the manufacturer’s protocols: Mouse CXCL2/MIP-2 Quantikine ELISA Kit (R&D Systems, Minneapolis, MN, USA), Mouse CXCL12/SDF-1 alpha Quantikine ELISA Kit (R&D Systems, Minneapolis, MN, USA), Mouse S100A8/S100A9 Heterodimer DuoSet ELISA (R&D Systems, Minneapolis, MN, USA), Mouse Neutrophil Elastase ELISA Kit (Abcam, Cambridge, UK), Mouse Myeloperoxidase (MPO) ELISA Kit (Abcam, Cambridge, UK), Mouse Lipocalin-2/NGAL DuoSet® ELISA (R&D Systems, Minneapolis, MN, USA), Mouse Lactoferrin (LTF) ELISA Kit (Abbexa Ltd, Cambridge, UK), Mouse in vitro SimpleStep MMP-8 ELISA Kit (Abcam, Cambridge, UK), Mouse MMP-9 ELISA Kit (Abcam, Cambridge, UK), Mouse MMP-25 ELISA Kit (Abbexa Ltd, Cambridge, UK), Mouse TIMP-1 ELISA Kit (Abcam, Cambridge, UK), Mouse TIMP-2 SimpleStep ELISA Kit (Abcam, Cambridge, UK), and Mouse BAFF ELISA Kit (Abcam, Cambridge, UK). .. Mouse spleens were isolated after CO 2 euthanasia of the animals and fixed overnight at 4 °C in neutral buffered 10% formalin solution (Sigma-Aldrich, Missouri, USA).

    Article Title: Neutrophil metalloproteinase driven spleen damage hampers infection control of trypanosomiasis.
    Article Snippet: .. Nature Communications | (2023) 14:5418 12 CXCL2/MIP-2 Quantikine ELISA Kit (R&D Systems, Minneapolis, MN, USA), Mouse CXCL12/SDF-1 alpha Quantikine ELISA Kit (R&D Systems, Minneapolis, MN, USA), Mouse S100A8/S100A9 Heterodimer DuoSet ELISA (R&D Systems, Minneapolis, MN, USA), Mouse Neutrophil Elastase ELISA Kit (Abcam, Cambridge, UK), Mouse Myeloperoxidase (MPO) ELISA Kit (Abcam, Cambridge, UK), Mouse Lipocalin-2/NGAL DuoSet® ELISA (R&D Systems, Minneapolis, MN, USA), Mouse Lactoferrin (LTF) ELISA Kit (Abbexa Ltd, Cambridge, UK), Mouse in vitro SimpleStep MMP-8 ELISA Kit (Abcam, Cambridge, UK), Mouse MMP-9 ELISA Kit (Abcam, Cambridge, UK), MouseMMP-25 ELISA Kit (Abbexa Ltd, Cambridge, UK), Mouse TIMP1 ELISA Kit (Abcam,Cambridge, UK),Mouse TIMP-2 SimpleStep ELISA Kit (Abcam, Cambridge, UK), and Mouse BAFF ELISA Kit (Abcam, Cambridge, UK). ..



    Similar Products

    95
    R&D Systems mouse cxcl12 sdf 1 alpha quantikine elisa kit
    Mouse Cxcl12 Sdf 1 Alpha Quantikine Elisa Kit, supplied by R&D Systems, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/mouse+cxcl12+sdf+1+alpha+quantikine+elisa+kit/Mouse+CXCL12%2FSDF-1+alpha+Quantikine+ELISA+Kit/bio_rxiv__64898__2026__04__21__720007-284-6-12
    Average 95 stars, based on 1 article reviews
    mouse cxcl12 sdf 1 alpha quantikine elisa kit - by Bioz Stars, 2026-11
    95/100 stars
      Buy from Supplier

    95
    R&D Systems elisa kit
    CCDC80 + fibroblasts recruit effector CD8 + T cells into the danger zone and drive their exhaustion <t>via</t> <t>CXCL12.</t> a Spatial deconvolution of effector CD8 + T cells (CD8_eff) and exhausted CD8 + T cells (CD8_exhau). b Spatial CellChat analysis of CXCL signaling between CD8 + T cell subsets and CCDC80 + or CCDC80 − fibroblasts. c Bubble plot of ligand-receptor pairs between CD8 + T cell subsets and CCDC80 + or CCDC80 − fibroblasts. d Ligand–receptor interaction analysis showing exclusive engagement of CCDC80 + fibroblasts in CXCL12–CXCR4 signaling with both CD8_eff and CD8_exhau cells. e Quantification of CD8_eff and CD8_exhau recruitment in intestinal-type GC (GC3). f Spatial clustering of GC6 sample. g Pseudotime trajectory from cluster 1 to cluster 0. h Representative trajectory (15 − 10/38/62) demonstrating spatial progression to exhaustion. i qRT-PCR for CCDC80 mRNA expression in NIH-3T3 fibroblasts. j Immunoblot for CCDC80 protein expression. k qRT-PCR for CXCL12 mRNA in CCDC80-overexpressing fibroblasts. l <t>ELISA</t> for quantification of CXCL12 secretion. m Schematic of fibroblast-CD8 + T cell co-culture experiment. n Flow cytometry for PD-1 expression on CD8 + T cells with or without CXCL12 blockade. o Flow cytometry for TIM-3 expression on CD8 + T cells with or without CXCL12 blockade
    Elisa Kit, supplied by R&D Systems, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/mouse+cxcl12+sdf+1+alpha+quantikine+elisa+kit/Mouse+CXCL12%2FSDF-1+alpha+Quantikine+ELISA+Kit/pmc12967633-51-9-13
    Average 95 stars, based on 1 article reviews
    elisa kit - by Bioz Stars, 2026-11
    95/100 stars
      Buy from Supplier

    95
    R&D Systems mouse cxcl12 elisa kit
    a . Representative images of MC38-OVA (left) and tumour growth (right) in C57BL/6J mice ( n = 5). b . Representative images of CT26 tumours (left) and tumour growth (right) in BALB/c mice ( n = 5). c . Schematic diagram illustrating the working principle of ATS-GNP adipocytolysis. ATS-GNP, containing a CaCO 3 core, is receptor-mediated for endocytosis. Upon reaching the acidic environment, ATS-GNP releases CO 2 gas, disrupting the adipose cell membrane. d . Tumour growth of MC38 tumours in C57BL/6J, BALB/c-Nude (left), and NSG (right) mice ( n = 5). e . Representative images of E0771 tumours at day 16 of the experiment in C57BL/6J mice following removal of PAT ( n = 5). f . Tumour weights of E0771 tumours at day 16 in C57BL/6J mice with the removal of PAT ( n = 5). g . Representative flow cytometry plots of CD45 + cells gated on live cells in MC38-OVA tumours. h . Violin plots showing the expression of CXCR7 across all cell types in CRC patients, analysed using the Kruskal-Wallis test. i . Editing strategy for constructing <t>Cxcl12</t> fl/fl cKO mouse. j . Experimental design for constructing Control and Cxcl12 fl/fl cKO mice bearing MC38-OVA tumours near PAT. k . Western blot analysis for verifying the knockout efficiency of Cxcl12 in PAT of Control mice and Cxcl12 fl/fl cKO mice. l . RT-qPCR analysis for verifying the Cxcl12 knockout efficiency in liver, spleen, uterus, and tumour tissues from Control mice and Cxcl12 fl/fl cKO mice ( n = 6). Data represent ≥ 3 independent experiments. P -values were calculated using two-way ANOVA with Tukey’s correction for multiple comparisons ( a -right, b -right, and d ), two-way ANOVA with Bonferroni’s correction for multiple comparisons ( f ), or a two-sided, unpaired Student’s t -test ( l ). Graphs display mean ± SD ( a , b , d , f , l ). Panels created with BioRender : c , i and j , Huaiqiang, J. https://biorender.com/cy7rgjm (2026).
    Mouse Cxcl12 Elisa Kit, supplied by R&D Systems, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/mouse+cxcl12+sdf+1+alpha+quantikine+elisa+kit/Mouse+CXCL12%2FSDF-1+alpha+Quantikine+ELISA+Kit/pmc12992116-296-7-11
    Average 95 stars, based on 1 article reviews
    mouse cxcl12 elisa kit - by Bioz Stars, 2026-11
    95/100 stars
      Buy from Supplier

    95
    Bio-Techne corporation mouse cxcl12/sdf-1 alpha quantikine elisa kit
    a . Representative images of MC38-OVA (left) and tumour growth (right) in C57BL/6J mice ( n = 5). b . Representative images of CT26 tumours (left) and tumour growth (right) in BALB/c mice ( n = 5). c . Schematic diagram illustrating the working principle of ATS-GNP adipocytolysis. ATS-GNP, containing a CaCO 3 core, is receptor-mediated for endocytosis. Upon reaching the acidic environment, ATS-GNP releases CO 2 gas, disrupting the adipose cell membrane. d . Tumour growth of MC38 tumours in C57BL/6J, BALB/c-Nude (left), and NSG (right) mice ( n = 5). e . Representative images of E0771 tumours at day 16 of the experiment in C57BL/6J mice following removal of PAT ( n = 5). f . Tumour weights of E0771 tumours at day 16 in C57BL/6J mice with the removal of PAT ( n = 5). g . Representative flow cytometry plots of CD45 + cells gated on live cells in MC38-OVA tumours. h . Violin plots showing the expression of CXCR7 across all cell types in CRC patients, analysed using the Kruskal-Wallis test. i . Editing strategy for constructing <t>Cxcl12</t> fl/fl cKO mouse. j . Experimental design for constructing Control and Cxcl12 fl/fl cKO mice bearing MC38-OVA tumours near PAT. k . Western blot analysis for verifying the knockout efficiency of Cxcl12 in PAT of Control mice and Cxcl12 fl/fl cKO mice. l . RT-qPCR analysis for verifying the Cxcl12 knockout efficiency in liver, spleen, uterus, and tumour tissues from Control mice and Cxcl12 fl/fl cKO mice ( n = 6). Data represent ≥ 3 independent experiments. P -values were calculated using two-way ANOVA with Tukey’s correction for multiple comparisons ( a -right, b -right, and d ), two-way ANOVA with Bonferroni’s correction for multiple comparisons ( f ), or a two-sided, unpaired Student’s t -test ( l ). Graphs display mean ± SD ( a , b , d , f , l ). Panels created with BioRender : c , i and j , Huaiqiang, J. https://biorender.com/cy7rgjm (2026).
    Mouse Cxcl12/Sdf 1 Alpha Quantikine Elisa Kit, supplied by Bio-Techne corporation, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/mouse+cxcl12+sdf+1+alpha+quantikine+elisa+kit/Mouse+CXCL12%2FSDF-1+alpha+Quantikine+ELISA+Kit/custom%40mcx120%4041371582
    Average 95 stars, based on 1 article reviews
    mouse cxcl12/sdf-1 alpha quantikine elisa kit - by Bioz Stars, 2026-11
    95/100 stars
      Buy from Supplier

    95
    R&D Systems elisa kits
    a . Representative images of MC38-OVA (left) and tumour growth (right) in C57BL/6J mice ( n = 5). b . Representative images of CT26 tumours (left) and tumour growth (right) in BALB/c mice ( n = 5). c . Schematic diagram illustrating the working principle of ATS-GNP adipocytolysis. ATS-GNP, containing a CaCO 3 core, is receptor-mediated for endocytosis. Upon reaching the acidic environment, ATS-GNP releases CO 2 gas, disrupting the adipose cell membrane. d . Tumour growth of MC38 tumours in C57BL/6J, BALB/c-Nude (left), and NSG (right) mice ( n = 5). e . Representative images of E0771 tumours at day 16 of the experiment in C57BL/6J mice following removal of PAT ( n = 5). f . Tumour weights of E0771 tumours at day 16 in C57BL/6J mice with the removal of PAT ( n = 5). g . Representative flow cytometry plots of CD45 + cells gated on live cells in MC38-OVA tumours. h . Violin plots showing the expression of CXCR7 across all cell types in CRC patients, analysed using the Kruskal-Wallis test. i . Editing strategy for constructing <t>Cxcl12</t> fl/fl cKO mouse. j . Experimental design for constructing Control and Cxcl12 fl/fl cKO mice bearing MC38-OVA tumours near PAT. k . Western blot analysis for verifying the knockout efficiency of Cxcl12 in PAT of Control mice and Cxcl12 fl/fl cKO mice. l . RT-qPCR analysis for verifying the Cxcl12 knockout efficiency in liver, spleen, uterus, and tumour tissues from Control mice and Cxcl12 fl/fl cKO mice ( n = 6). Data represent ≥ 3 independent experiments. P -values were calculated using two-way ANOVA with Tukey’s correction for multiple comparisons ( a -right, b -right, and d ), two-way ANOVA with Bonferroni’s correction for multiple comparisons ( f ), or a two-sided, unpaired Student’s t -test ( l ). Graphs display mean ± SD ( a , b , d , f , l ). Panels created with BioRender : c , i and j , Huaiqiang, J. https://biorender.com/cy7rgjm (2026).
    Elisa Kits, supplied by R&D Systems, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/mouse+cxcl12+sdf+1+alpha+quantikine+elisa+kit/Mouse+CXCL12%2FSDF-1+alpha+Quantikine+ELISA+Kit/pm41270997-89-6-8
    Average 95 stars, based on 1 article reviews
    elisa kits - by Bioz Stars, 2026-11
    95/100 stars
      Buy from Supplier

    95
    R&D Systems mouse cxcl12
    a . Representative images of MC38-OVA (left) and tumour growth (right) in C57BL/6J mice ( n = 5). b . Representative images of CT26 tumours (left) and tumour growth (right) in BALB/c mice ( n = 5). c . Schematic diagram illustrating the working principle of ATS-GNP adipocytolysis. ATS-GNP, containing a CaCO 3 core, is receptor-mediated for endocytosis. Upon reaching the acidic environment, ATS-GNP releases CO 2 gas, disrupting the adipose cell membrane. d . Tumour growth of MC38 tumours in C57BL/6J, BALB/c-Nude (left), and NSG (right) mice ( n = 5). e . Representative images of E0771 tumours at day 16 of the experiment in C57BL/6J mice following removal of PAT ( n = 5). f . Tumour weights of E0771 tumours at day 16 in C57BL/6J mice with the removal of PAT ( n = 5). g . Representative flow cytometry plots of CD45 + cells gated on live cells in MC38-OVA tumours. h . Violin plots showing the expression of CXCR7 across all cell types in CRC patients, analysed using the Kruskal-Wallis test. i . Editing strategy for constructing <t>Cxcl12</t> fl/fl cKO mouse. j . Experimental design for constructing Control and Cxcl12 fl/fl cKO mice bearing MC38-OVA tumours near PAT. k . Western blot analysis for verifying the knockout efficiency of Cxcl12 in PAT of Control mice and Cxcl12 fl/fl cKO mice. l . RT-qPCR analysis for verifying the Cxcl12 knockout efficiency in liver, spleen, uterus, and tumour tissues from Control mice and Cxcl12 fl/fl cKO mice ( n = 6). Data represent ≥ 3 independent experiments. P -values were calculated using two-way ANOVA with Tukey’s correction for multiple comparisons ( a -right, b -right, and d ), two-way ANOVA with Bonferroni’s correction for multiple comparisons ( f ), or a two-sided, unpaired Student’s t -test ( l ). Graphs display mean ± SD ( a , b , d , f , l ). Panels created with BioRender : c , i and j , Huaiqiang, J. https://biorender.com/cy7rgjm (2026).
    Mouse Cxcl12, supplied by R&D Systems, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/mouse+cxcl12+sdf+1+alpha+quantikine+elisa+kit/Mouse+CXCL12%2FSDF-1+alpha+Quantikine+ELISA+Kit/pm41270997-89-0-8
    Average 95 stars, based on 1 article reviews
    mouse cxcl12 - by Bioz Stars, 2026-11
    95/100 stars
      Buy from Supplier

    Image Search Results


    CCDC80 + fibroblasts recruit effector CD8 + T cells into the danger zone and drive their exhaustion via CXCL12. a Spatial deconvolution of effector CD8 + T cells (CD8_eff) and exhausted CD8 + T cells (CD8_exhau). b Spatial CellChat analysis of CXCL signaling between CD8 + T cell subsets and CCDC80 + or CCDC80 − fibroblasts. c Bubble plot of ligand-receptor pairs between CD8 + T cell subsets and CCDC80 + or CCDC80 − fibroblasts. d Ligand–receptor interaction analysis showing exclusive engagement of CCDC80 + fibroblasts in CXCL12–CXCR4 signaling with both CD8_eff and CD8_exhau cells. e Quantification of CD8_eff and CD8_exhau recruitment in intestinal-type GC (GC3). f Spatial clustering of GC6 sample. g Pseudotime trajectory from cluster 1 to cluster 0. h Representative trajectory (15 − 10/38/62) demonstrating spatial progression to exhaustion. i qRT-PCR for CCDC80 mRNA expression in NIH-3T3 fibroblasts. j Immunoblot for CCDC80 protein expression. k qRT-PCR for CXCL12 mRNA in CCDC80-overexpressing fibroblasts. l ELISA for quantification of CXCL12 secretion. m Schematic of fibroblast-CD8 + T cell co-culture experiment. n Flow cytometry for PD-1 expression on CD8 + T cells with or without CXCL12 blockade. o Flow cytometry for TIM-3 expression on CD8 + T cells with or without CXCL12 blockade

    Journal: Apoptosis

    Article Title: Spatially defined danger zone shapes gastric cancer progression through CCDC80 + fibroblast–induced CD8 + T cell dysfunction

    doi: 10.1007/s10495-026-02287-1

    Figure Lengend Snippet: CCDC80 + fibroblasts recruit effector CD8 + T cells into the danger zone and drive their exhaustion via CXCL12. a Spatial deconvolution of effector CD8 + T cells (CD8_eff) and exhausted CD8 + T cells (CD8_exhau). b Spatial CellChat analysis of CXCL signaling between CD8 + T cell subsets and CCDC80 + or CCDC80 − fibroblasts. c Bubble plot of ligand-receptor pairs between CD8 + T cell subsets and CCDC80 + or CCDC80 − fibroblasts. d Ligand–receptor interaction analysis showing exclusive engagement of CCDC80 + fibroblasts in CXCL12–CXCR4 signaling with both CD8_eff and CD8_exhau cells. e Quantification of CD8_eff and CD8_exhau recruitment in intestinal-type GC (GC3). f Spatial clustering of GC6 sample. g Pseudotime trajectory from cluster 1 to cluster 0. h Representative trajectory (15 − 10/38/62) demonstrating spatial progression to exhaustion. i qRT-PCR for CCDC80 mRNA expression in NIH-3T3 fibroblasts. j Immunoblot for CCDC80 protein expression. k qRT-PCR for CXCL12 mRNA in CCDC80-overexpressing fibroblasts. l ELISA for quantification of CXCL12 secretion. m Schematic of fibroblast-CD8 + T cell co-culture experiment. n Flow cytometry for PD-1 expression on CD8 + T cells with or without CXCL12 blockade. o Flow cytometry for TIM-3 expression on CD8 + T cells with or without CXCL12 blockade

    Article Snippet: The collected supernatant was assayed for CXCL12 using an ELISA kit (Cat# MCX120, R&D Systems, Minneapolis, MN, USA), following the manufacturer’s instructions.

    Techniques: Quantitative RT-PCR, Expressing, Western Blot, Enzyme-linked Immunosorbent Assay, Co-Culture Assay, Flow Cytometry

    a . Representative images of MC38-OVA (left) and tumour growth (right) in C57BL/6J mice ( n = 5). b . Representative images of CT26 tumours (left) and tumour growth (right) in BALB/c mice ( n = 5). c . Schematic diagram illustrating the working principle of ATS-GNP adipocytolysis. ATS-GNP, containing a CaCO 3 core, is receptor-mediated for endocytosis. Upon reaching the acidic environment, ATS-GNP releases CO 2 gas, disrupting the adipose cell membrane. d . Tumour growth of MC38 tumours in C57BL/6J, BALB/c-Nude (left), and NSG (right) mice ( n = 5). e . Representative images of E0771 tumours at day 16 of the experiment in C57BL/6J mice following removal of PAT ( n = 5). f . Tumour weights of E0771 tumours at day 16 in C57BL/6J mice with the removal of PAT ( n = 5). g . Representative flow cytometry plots of CD45 + cells gated on live cells in MC38-OVA tumours. h . Violin plots showing the expression of CXCR7 across all cell types in CRC patients, analysed using the Kruskal-Wallis test. i . Editing strategy for constructing Cxcl12 fl/fl cKO mouse. j . Experimental design for constructing Control and Cxcl12 fl/fl cKO mice bearing MC38-OVA tumours near PAT. k . Western blot analysis for verifying the knockout efficiency of Cxcl12 in PAT of Control mice and Cxcl12 fl/fl cKO mice. l . RT-qPCR analysis for verifying the Cxcl12 knockout efficiency in liver, spleen, uterus, and tumour tissues from Control mice and Cxcl12 fl/fl cKO mice ( n = 6). Data represent ≥ 3 independent experiments. P -values were calculated using two-way ANOVA with Tukey’s correction for multiple comparisons ( a -right, b -right, and d ), two-way ANOVA with Bonferroni’s correction for multiple comparisons ( f ), or a two-sided, unpaired Student’s t -test ( l ). Graphs display mean ± SD ( a , b , d , f , l ). Panels created with BioRender : c , i and j , Huaiqiang, J. https://biorender.com/cy7rgjm (2026).

    Journal: Nature Cell Biology

    Article Title: Peritumoural adipose tissue drives immune evasion in colorectal cancer via adipose–mesenchymal transformation

    doi: 10.1038/s41556-026-01885-0

    Figure Lengend Snippet: a . Representative images of MC38-OVA (left) and tumour growth (right) in C57BL/6J mice ( n = 5). b . Representative images of CT26 tumours (left) and tumour growth (right) in BALB/c mice ( n = 5). c . Schematic diagram illustrating the working principle of ATS-GNP adipocytolysis. ATS-GNP, containing a CaCO 3 core, is receptor-mediated for endocytosis. Upon reaching the acidic environment, ATS-GNP releases CO 2 gas, disrupting the adipose cell membrane. d . Tumour growth of MC38 tumours in C57BL/6J, BALB/c-Nude (left), and NSG (right) mice ( n = 5). e . Representative images of E0771 tumours at day 16 of the experiment in C57BL/6J mice following removal of PAT ( n = 5). f . Tumour weights of E0771 tumours at day 16 in C57BL/6J mice with the removal of PAT ( n = 5). g . Representative flow cytometry plots of CD45 + cells gated on live cells in MC38-OVA tumours. h . Violin plots showing the expression of CXCR7 across all cell types in CRC patients, analysed using the Kruskal-Wallis test. i . Editing strategy for constructing Cxcl12 fl/fl cKO mouse. j . Experimental design for constructing Control and Cxcl12 fl/fl cKO mice bearing MC38-OVA tumours near PAT. k . Western blot analysis for verifying the knockout efficiency of Cxcl12 in PAT of Control mice and Cxcl12 fl/fl cKO mice. l . RT-qPCR analysis for verifying the Cxcl12 knockout efficiency in liver, spleen, uterus, and tumour tissues from Control mice and Cxcl12 fl/fl cKO mice ( n = 6). Data represent ≥ 3 independent experiments. P -values were calculated using two-way ANOVA with Tukey’s correction for multiple comparisons ( a -right, b -right, and d ), two-way ANOVA with Bonferroni’s correction for multiple comparisons ( f ), or a two-sided, unpaired Student’s t -test ( l ). Graphs display mean ± SD ( a , b , d , f , l ). Panels created with BioRender : c , i and j , Huaiqiang, J. https://biorender.com/cy7rgjm (2026).

    Article Snippet: The CXCL12 concentrations were determined using the Mouse CXCL12 ELISA kit (R&D system).

    Techniques: Membrane, Flow Cytometry, Expressing, Control, Western Blot, Knock-Out, Quantitative RT-PCR

    a , Cell–cell communication analysis based on ligand–receptor interactions (top six) between stromal cells and lymphocytes in tVAT (left) and a comparison between tVAT, dVAT and tumour (right). b , Marked CXCL12–CXCR4 interactions among CD8 + T cells, CD4 + T cells, B cells, plasma cells and stromal cell populations in tVAT, dVAT and tumour. The width of the lines represents the probability of communication. c , Violin plots showing the expression of CXCL12 (top) and CXCR4 (bottom) across all cell types in patients with CRC. d , Violin plots comparing the expression of CXCL12 in dVAT versus tVAT (top) and tumour versus tVAT (bottom) in patients with CRC, analysed using a two-sided Wilcoxon test. e , Experimental design for the PAT C57BL/6J mouse model treated with IgG or anti-CXCL12 antibody (left), and representative MC38 tumour images at day 16 of the experiment (right) ( n = 5). f , Tumour growth (left) and tumour weights (right) of MC38 tumours at day 16 of the experiment in C57BL/6J mice ( n = 5). g , Representative MC38 tumour images (left) and tumour growth (right) of experiments in control and Cxcl12 fl/fl cKO mice ( n = 6). h , Tumour weights of MC38 tumours in control and Cxcl12 fl/fl cKO mice at day 16 of the experiment ( n = 6). i , Flow cytometry analysis of the infiltration of various CXCR4 + immune cells in MC38 tumours in Control and Cxcl12 fl/fl cKO mice ( n = 6). j , Schematic diagram of the chemotaxis assay using T cells as ‘sensors’ and conditional medium as a ‘sink’ (left), and the aggregated trajectories of control or CXCL12-induced T cells migrating for 1 h (right). k , Quantitative analysis of CXCR4 + CD45.1 + T cells in MC38 tumours with and without removal of PAT or contralateral inguinal adipose tissue (control) by flow cytometry ( n = 5). Data represent ≥3 independent experiments. Statistical significance was assessed by a two-sided permutation test ( a ), two-sided unpaired Student’s t -test ( f right, h and i ), one-way analysis of variance (ANOVA) with Tukey’s correction for multiple comparisons ( k right) or two-way ANOVA ( f left and g right). Graphs display mean ± s.d. ( f – i , k ). Panels created with BioRender : e and k , Huaiqiang, J. https://biorender.com/ovq2e39 (2026).

    Journal: Nature Cell Biology

    Article Title: Peritumoural adipose tissue drives immune evasion in colorectal cancer via adipose–mesenchymal transformation

    doi: 10.1038/s41556-026-01885-0

    Figure Lengend Snippet: a , Cell–cell communication analysis based on ligand–receptor interactions (top six) between stromal cells and lymphocytes in tVAT (left) and a comparison between tVAT, dVAT and tumour (right). b , Marked CXCL12–CXCR4 interactions among CD8 + T cells, CD4 + T cells, B cells, plasma cells and stromal cell populations in tVAT, dVAT and tumour. The width of the lines represents the probability of communication. c , Violin plots showing the expression of CXCL12 (top) and CXCR4 (bottom) across all cell types in patients with CRC. d , Violin plots comparing the expression of CXCL12 in dVAT versus tVAT (top) and tumour versus tVAT (bottom) in patients with CRC, analysed using a two-sided Wilcoxon test. e , Experimental design for the PAT C57BL/6J mouse model treated with IgG or anti-CXCL12 antibody (left), and representative MC38 tumour images at day 16 of the experiment (right) ( n = 5). f , Tumour growth (left) and tumour weights (right) of MC38 tumours at day 16 of the experiment in C57BL/6J mice ( n = 5). g , Representative MC38 tumour images (left) and tumour growth (right) of experiments in control and Cxcl12 fl/fl cKO mice ( n = 6). h , Tumour weights of MC38 tumours in control and Cxcl12 fl/fl cKO mice at day 16 of the experiment ( n = 6). i , Flow cytometry analysis of the infiltration of various CXCR4 + immune cells in MC38 tumours in Control and Cxcl12 fl/fl cKO mice ( n = 6). j , Schematic diagram of the chemotaxis assay using T cells as ‘sensors’ and conditional medium as a ‘sink’ (left), and the aggregated trajectories of control or CXCL12-induced T cells migrating for 1 h (right). k , Quantitative analysis of CXCR4 + CD45.1 + T cells in MC38 tumours with and without removal of PAT or contralateral inguinal adipose tissue (control) by flow cytometry ( n = 5). Data represent ≥3 independent experiments. Statistical significance was assessed by a two-sided permutation test ( a ), two-sided unpaired Student’s t -test ( f right, h and i ), one-way analysis of variance (ANOVA) with Tukey’s correction for multiple comparisons ( k right) or two-way ANOVA ( f left and g right). Graphs display mean ± s.d. ( f – i , k ). Panels created with BioRender : e and k , Huaiqiang, J. https://biorender.com/ovq2e39 (2026).

    Article Snippet: The CXCL12 concentrations were determined using the Mouse CXCL12 ELISA kit (R&D system).

    Techniques: Comparison, Clinical Proteomics, Expressing, Control, Flow Cytometry, Chemotaxis Assay

    a . UMAP plot of VAT-associated stromal cells in tVAT and dVAT from CRC patients. The 8 clusters, labelled by inferred cell types, are denoted by colour. b . Dot plot showing RNA expression of marker genes used to define pAC, adCAF, and APC subclusters. Circle size represents the log-normalized P -value, while colour intensity indicates the log-transformed mean expression of marker genes. c . Sorting strategy for isolating adCAFs from mouse PAT by flow cytometry. d . RNA sequencing analysis of adCAF markers in sorted adCAF-enriched stromal cells and non-adCAF stromal cells ( n = 4). Statistical significance was assessed using a two-sided, unpaired Student’s t -test. e . RNA sequencing analysis of adipogenesis markers in sorted adCAF-enriched stromal cells and non-adCAF stromal cells ( n = 4). Statistical significance was assessed using a two-sided, unpaired Student’s t -test. f . Representative images of the morphology of sorted adCAF-enriched stromal cells and non-adCAF stromal cells. Scale bar = 500 μm. g . Cross-tissue interactions analysis based on ligand-receptor pairs between adCAFs and tumour cells (left) and a comparison between tVAT and dVAT (right). A two-sided permutation test was used to determine the significance of pathways. h . Western blot analysis of CXCL12 protein expression in sorted adCAF-enriched stromal cells and non-adCAF stromal cells ( n = 3). The data are presented as a box-and-whisker graph (bounds of box: first to third quartile, bottom and top line: minimum to maximum, central line: median) for ( d - e ).

    Journal: Nature Cell Biology

    Article Title: Peritumoural adipose tissue drives immune evasion in colorectal cancer via adipose–mesenchymal transformation

    doi: 10.1038/s41556-026-01885-0

    Figure Lengend Snippet: a . UMAP plot of VAT-associated stromal cells in tVAT and dVAT from CRC patients. The 8 clusters, labelled by inferred cell types, are denoted by colour. b . Dot plot showing RNA expression of marker genes used to define pAC, adCAF, and APC subclusters. Circle size represents the log-normalized P -value, while colour intensity indicates the log-transformed mean expression of marker genes. c . Sorting strategy for isolating adCAFs from mouse PAT by flow cytometry. d . RNA sequencing analysis of adCAF markers in sorted adCAF-enriched stromal cells and non-adCAF stromal cells ( n = 4). Statistical significance was assessed using a two-sided, unpaired Student’s t -test. e . RNA sequencing analysis of adipogenesis markers in sorted adCAF-enriched stromal cells and non-adCAF stromal cells ( n = 4). Statistical significance was assessed using a two-sided, unpaired Student’s t -test. f . Representative images of the morphology of sorted adCAF-enriched stromal cells and non-adCAF stromal cells. Scale bar = 500 μm. g . Cross-tissue interactions analysis based on ligand-receptor pairs between adCAFs and tumour cells (left) and a comparison between tVAT and dVAT (right). A two-sided permutation test was used to determine the significance of pathways. h . Western blot analysis of CXCL12 protein expression in sorted adCAF-enriched stromal cells and non-adCAF stromal cells ( n = 3). The data are presented as a box-and-whisker graph (bounds of box: first to third quartile, bottom and top line: minimum to maximum, central line: median) for ( d - e ).

    Article Snippet: The CXCL12 concentrations were determined using the Mouse CXCL12 ELISA kit (R&D system).

    Techniques: RNA Expression, Marker, Transformation Assay, Expressing, Flow Cytometry, RNA Sequencing, Comparison, Western Blot, Whisker Assay

    a , UMAP of all stromal cells in tVAT, dVAT, tumour and normal from patients with CRC, with ten clusters labelled by inferred cell types. Major lineages included ASCs, pACs, CAFs, pericytes (PCs) and mesothelial cells (Mesos). b , Heatmap displaying the distribution of eight stromal cell subtypes across different tissue types. c , UMAP of eight subsets of VAT-associated stromal cells in tVAT and dVAT from patients with CRC, including ASCs, pACs and adCAFs. d , Beeswarm plot showing the distribution and abundance of VAT-associated stromal cell types in Nhoods between tVAT and dVAT. e , Stack plot displaying the abundance of the eight VAT-associated stromal cell subsets in dVAT and tVAT. f , Heatmap showing the RNA expression of various marker genes in VAT-associated stromal cell types, including ASC/pAC markers, CAF markers, cytokines and stromal markers. g , Representative multiplex immunofluorescence images showing the presence of adCAFs in tVAT samples from patients with CRC. Scale bar, 10 μm. DAPI, 4,6-diamidino-2-phenylindole. h , Relative expression levels of multiple cytokines and protumoural factors in adCAF-enriched stromal cells ( n = 4) and non-adCAF stromal cells ( n = 4) derived from the PAT of mice xenograft models. The data are presented as a box-and-whisker graph (bounds of box show first to third quartile, bottom and top line show minimum to maximum and the central line shows the median). i , Cell–cell communication analysis based on ligand–receptor pairs (top six) between adCAFs and lymphocytes in tVAT (left) and a comparison between tVAT and dVAT (right). j , RT–qPCR (left) and ELISA (right) detecting the RNA expression and protein secretion of CXCL12 in sorted adCAF-enriched stromal cells and non-adCAF stromal cells from PAT of mice. Data represent ≥3 independent experiments. All data are shown as mean ± s.d. and statistical significance was assessed by a two-sided, unpaired Wilcoxon test ( h ), two-sided permutation test ( i ) and Student’s t -test ( j ).

    Journal: Nature Cell Biology

    Article Title: Peritumoural adipose tissue drives immune evasion in colorectal cancer via adipose–mesenchymal transformation

    doi: 10.1038/s41556-026-01885-0

    Figure Lengend Snippet: a , UMAP of all stromal cells in tVAT, dVAT, tumour and normal from patients with CRC, with ten clusters labelled by inferred cell types. Major lineages included ASCs, pACs, CAFs, pericytes (PCs) and mesothelial cells (Mesos). b , Heatmap displaying the distribution of eight stromal cell subtypes across different tissue types. c , UMAP of eight subsets of VAT-associated stromal cells in tVAT and dVAT from patients with CRC, including ASCs, pACs and adCAFs. d , Beeswarm plot showing the distribution and abundance of VAT-associated stromal cell types in Nhoods between tVAT and dVAT. e , Stack plot displaying the abundance of the eight VAT-associated stromal cell subsets in dVAT and tVAT. f , Heatmap showing the RNA expression of various marker genes in VAT-associated stromal cell types, including ASC/pAC markers, CAF markers, cytokines and stromal markers. g , Representative multiplex immunofluorescence images showing the presence of adCAFs in tVAT samples from patients with CRC. Scale bar, 10 μm. DAPI, 4,6-diamidino-2-phenylindole. h , Relative expression levels of multiple cytokines and protumoural factors in adCAF-enriched stromal cells ( n = 4) and non-adCAF stromal cells ( n = 4) derived from the PAT of mice xenograft models. The data are presented as a box-and-whisker graph (bounds of box show first to third quartile, bottom and top line show minimum to maximum and the central line shows the median). i , Cell–cell communication analysis based on ligand–receptor pairs (top six) between adCAFs and lymphocytes in tVAT (left) and a comparison between tVAT and dVAT (right). j , RT–qPCR (left) and ELISA (right) detecting the RNA expression and protein secretion of CXCL12 in sorted adCAF-enriched stromal cells and non-adCAF stromal cells from PAT of mice. Data represent ≥3 independent experiments. All data are shown as mean ± s.d. and statistical significance was assessed by a two-sided, unpaired Wilcoxon test ( h ), two-sided permutation test ( i ) and Student’s t -test ( j ).

    Article Snippet: The CXCL12 concentrations were determined using the Mouse CXCL12 ELISA kit (R&D system).

    Techniques: RNA Expression, Marker, Multiplex Assay, Immunofluorescence, Expressing, Derivative Assay, Whisker Assay, Comparison, Quantitative RT-PCR, Enzyme-linked Immunosorbent Assay

    a . UMAP of all cells in tVAT and dVAT from 5 CRC patients, with 16 clusters labelled by inferred cell types. Major lineages included various immunocytes, VAT-associated stromal cells, adipocytes (ACs), endothelial cells (ECs), pericytes (PCs) and mesothelial cells (Mesos). b . Heatmap of representative marker genes across all cell populations. c . UMAP of 6 subsets of ACs in tVAT and dVAT from 5 CRC patients. d . Beeswarm plot showing the distribution and abundance of ACs in Nhoods between tVAT and dVAT. e . Box plot to compare the abundance of ACs in dVAT ( n = 5) and tVAT ( n = 5). P -values were calculated using a two-side Wilcoxon test. f . Cell-cell communication analysis based on ligand-receptor interactions (top 3) between CD8 + T cells and adipocytes, and between CD8 + T cells and VAT-associated stromal cells in tVAT. A two-sided permutation test was used to determine the significance of pathways. Only significant ligand-receptor pairs ( P < 0.05) are shown. Dot size encodes the interaction score, and colour scale indicates the communication probability. g . Violin plots showing the expression of CXCL12, VAT-associated markers, and CAF-associated markers in adipocytes and VAT-associated stromal cells from CRC patients. h . UMAP of 8 subsets of VAT-associated stromal cells in tVAT and dVAT from 5 CRC patients, including APCs, pACs and adipocyte-derived cancer-associated fibroasts (adCAFs). The 8 clusters, labelled by inferred cell types, are denoted by colour. i . Beeswarm plot showing the distribution and abundance of VAT-associated stromal cell types in Nhoods between tVAT ( n = 5) and dVAT ( n = 5). j . Box plot to compare the abundance of VAT-associated stromal cells in dVAT and tVAT. P -values were calculated using a two-side Wilcoxon test. k . Heatmap showing the RNA expression patterns of representative marker genes across all cell populations, including CAF markers, stromal markers, APC/pAC markers, white/brown/beige fat markers, and cytokines and growth markers. The data are presented as a box-and-whisker graph (bounds of box: first to third quartile, bottom and top line: minimum to maximum, central line: median) for ( e , j ).

    Journal: Nature Cell Biology

    Article Title: Peritumoural adipose tissue drives immune evasion in colorectal cancer via adipose–mesenchymal transformation

    doi: 10.1038/s41556-026-01885-0

    Figure Lengend Snippet: a . UMAP of all cells in tVAT and dVAT from 5 CRC patients, with 16 clusters labelled by inferred cell types. Major lineages included various immunocytes, VAT-associated stromal cells, adipocytes (ACs), endothelial cells (ECs), pericytes (PCs) and mesothelial cells (Mesos). b . Heatmap of representative marker genes across all cell populations. c . UMAP of 6 subsets of ACs in tVAT and dVAT from 5 CRC patients. d . Beeswarm plot showing the distribution and abundance of ACs in Nhoods between tVAT and dVAT. e . Box plot to compare the abundance of ACs in dVAT ( n = 5) and tVAT ( n = 5). P -values were calculated using a two-side Wilcoxon test. f . Cell-cell communication analysis based on ligand-receptor interactions (top 3) between CD8 + T cells and adipocytes, and between CD8 + T cells and VAT-associated stromal cells in tVAT. A two-sided permutation test was used to determine the significance of pathways. Only significant ligand-receptor pairs ( P < 0.05) are shown. Dot size encodes the interaction score, and colour scale indicates the communication probability. g . Violin plots showing the expression of CXCL12, VAT-associated markers, and CAF-associated markers in adipocytes and VAT-associated stromal cells from CRC patients. h . UMAP of 8 subsets of VAT-associated stromal cells in tVAT and dVAT from 5 CRC patients, including APCs, pACs and adipocyte-derived cancer-associated fibroasts (adCAFs). The 8 clusters, labelled by inferred cell types, are denoted by colour. i . Beeswarm plot showing the distribution and abundance of VAT-associated stromal cell types in Nhoods between tVAT ( n = 5) and dVAT ( n = 5). j . Box plot to compare the abundance of VAT-associated stromal cells in dVAT and tVAT. P -values were calculated using a two-side Wilcoxon test. k . Heatmap showing the RNA expression patterns of representative marker genes across all cell populations, including CAF markers, stromal markers, APC/pAC markers, white/brown/beige fat markers, and cytokines and growth markers. The data are presented as a box-and-whisker graph (bounds of box: first to third quartile, bottom and top line: minimum to maximum, central line: median) for ( e , j ).

    Article Snippet: The CXCL12 concentrations were determined using the Mouse CXCL12 ELISA kit (R&D system).

    Techniques: Marker, Expressing, Derivative Assay, RNA Expression, Whisker Assay

    a , Experimental design for constructing Control and Mdk DTR cKO mice bearing MC38 tumours near PAT, followed by αPD-1 therapy. b , c , Representative MC38 tumour images ( b ), tumour weights ( c left) and tumour growth ( c right) in control and Mdk DTR cKO mice treated with IgG or anti-PD-1 ( n = 6). d , Flow cytometry analysis of the infiltration of immunocytes, including T cells, CD4 + T cells, CD8 + T cells, and tumour-specific CD8 + T cells, CXCR4 + immunocytes, CXCR4 + T cell, CXCR4 + CD4 + T cell, CXCR4 + CD8 + T cell and CXCR4 + tumour-specific T cell in MC38-OVA tumours from the four treatment groups ( n = 6). e , f , Representative MC38 tumour images ( e ) and tumour weights ( f ) of the experiment in mice treated with anti-CXCL12 and/or anti-PD-1 ( n = 5). g , Representative MRI image of CRC tumour and corresponding tVAT area region of CR and non-CR patients pre- and post-immuno-chemoradiotherapy. The yellow area represents the tVAT area, whereas the red area denotes the tumour region. Note that the mass visible in the intestinal lumen (top right) is faecal material. h , Pre-treatment tVAT area difference based on 3D Slicer between CR ( n = 30) and non-CR ( n = 37) patients. The data are presented as a box-and-whisker graph (bounds of box show first to third quartile, bottom and top line show minimum to maximum and the central line shows the median). i , ROC plot of response predicting ability of pre-treatment PAT area in immuno-chemoradiotherapy of proficient mismatch repair patients with CRC, compared with conventional indexes, including CPS, TPS, CEA and CA199 ( n = 67) with optimal cutoff. j , Comparison of pCR ratio in tVAT high and low group according to the optimal cutoff. k , Graphical abstract depicting how tumours reshape the stromal environment in tVAT and how tVAT competes for immunocytes from the tumour to promote immune escape. Data represent ≥3 independent experiments. Statistical significance was assessed using a two-sided, unpaired Student’s t -test ( d , h ), one-way ANOVA with Tukey’s correction for multiple comparisons ( c left, f ) or two-way ANOVA with Tukey’s correction for multiple comparisons ( c right). Graphs display mean ± s.d. ( c , d , f , h ). Panels created with BioRender : a and k , Huaiqiang, J. https://biorender.com/e5jwcye (2026).

    Journal: Nature Cell Biology

    Article Title: Peritumoural adipose tissue drives immune evasion in colorectal cancer via adipose–mesenchymal transformation

    doi: 10.1038/s41556-026-01885-0

    Figure Lengend Snippet: a , Experimental design for constructing Control and Mdk DTR cKO mice bearing MC38 tumours near PAT, followed by αPD-1 therapy. b , c , Representative MC38 tumour images ( b ), tumour weights ( c left) and tumour growth ( c right) in control and Mdk DTR cKO mice treated with IgG or anti-PD-1 ( n = 6). d , Flow cytometry analysis of the infiltration of immunocytes, including T cells, CD4 + T cells, CD8 + T cells, and tumour-specific CD8 + T cells, CXCR4 + immunocytes, CXCR4 + T cell, CXCR4 + CD4 + T cell, CXCR4 + CD8 + T cell and CXCR4 + tumour-specific T cell in MC38-OVA tumours from the four treatment groups ( n = 6). e , f , Representative MC38 tumour images ( e ) and tumour weights ( f ) of the experiment in mice treated with anti-CXCL12 and/or anti-PD-1 ( n = 5). g , Representative MRI image of CRC tumour and corresponding tVAT area region of CR and non-CR patients pre- and post-immuno-chemoradiotherapy. The yellow area represents the tVAT area, whereas the red area denotes the tumour region. Note that the mass visible in the intestinal lumen (top right) is faecal material. h , Pre-treatment tVAT area difference based on 3D Slicer between CR ( n = 30) and non-CR ( n = 37) patients. The data are presented as a box-and-whisker graph (bounds of box show first to third quartile, bottom and top line show minimum to maximum and the central line shows the median). i , ROC plot of response predicting ability of pre-treatment PAT area in immuno-chemoradiotherapy of proficient mismatch repair patients with CRC, compared with conventional indexes, including CPS, TPS, CEA and CA199 ( n = 67) with optimal cutoff. j , Comparison of pCR ratio in tVAT high and low group according to the optimal cutoff. k , Graphical abstract depicting how tumours reshape the stromal environment in tVAT and how tVAT competes for immunocytes from the tumour to promote immune escape. Data represent ≥3 independent experiments. Statistical significance was assessed using a two-sided, unpaired Student’s t -test ( d , h ), one-way ANOVA with Tukey’s correction for multiple comparisons ( c left, f ) or two-way ANOVA with Tukey’s correction for multiple comparisons ( c right). Graphs display mean ± s.d. ( c , d , f , h ). Panels created with BioRender : a and k , Huaiqiang, J. https://biorender.com/e5jwcye (2026).

    Article Snippet: The CXCL12 concentrations were determined using the Mouse CXCL12 ELISA kit (R&D system).

    Techniques: Control, Flow Cytometry, Whisker Assay, Comparison

    a . Editing strategy for constructing Mdk DTR mouse. b . Flow cytometry representative plots and bar graphs for verifying the elimination efficiency of adCAFs (FAP + PDGFRB + MDK + stromal cells) in PAT of Control mice and Mdk DTR cKO mice. c . Experimental design for combination therapy with αCXCL12 and αPD-1 in mice bearing MC38-OVA tumours near PAT. d . MC38 tumour weights of the experiment in mice treated with αCXCL12 and/or αPD-1 ( n = 6). e . Flow cytometry analysis of the infiltration of immunocytes, including T cells, CD4 + T cells, CD8 + T cells, and tumour-specific CD8 + T cells in MC38-OVA tumours from the 4 treatment groups ( n = 6). f . Flow cytometry analysis of the infiltration of CXCR4 + immunocytes, including CXCR4 + T cell, CXCR4 + CD4 + T cell and CXCR4 + CD8 + T cell in MC38-OVA tumours from the 4 treatment groups ( n = 6). g . Boxplot of difference of tVAT area in CR and non-CR patients with T3 or T4 stage separately. The data are presented as a box-and-whisker graph (bounds of box: first to third quartile, bottom and top line: minimum to maximum, central line: median). h . ROC plot of prediction ability of tVAT area in patients with T3 or T4 stage separately. Data represent ≥ 3 independent experiments. P -values were calculated using a two-sided, unpaired Student’s t -test ( b , e - g ) and two-way ANOVA with Tukey’s correction for multiple comparisons ( d ). Graphs display mean ± SD ( b , d , e - g ). Panels created with BioRender : a and c , Huaiqiang, J. https://biorender.com/33r2gmm (2026).

    Journal: Nature Cell Biology

    Article Title: Peritumoural adipose tissue drives immune evasion in colorectal cancer via adipose–mesenchymal transformation

    doi: 10.1038/s41556-026-01885-0

    Figure Lengend Snippet: a . Editing strategy for constructing Mdk DTR mouse. b . Flow cytometry representative plots and bar graphs for verifying the elimination efficiency of adCAFs (FAP + PDGFRB + MDK + stromal cells) in PAT of Control mice and Mdk DTR cKO mice. c . Experimental design for combination therapy with αCXCL12 and αPD-1 in mice bearing MC38-OVA tumours near PAT. d . MC38 tumour weights of the experiment in mice treated with αCXCL12 and/or αPD-1 ( n = 6). e . Flow cytometry analysis of the infiltration of immunocytes, including T cells, CD4 + T cells, CD8 + T cells, and tumour-specific CD8 + T cells in MC38-OVA tumours from the 4 treatment groups ( n = 6). f . Flow cytometry analysis of the infiltration of CXCR4 + immunocytes, including CXCR4 + T cell, CXCR4 + CD4 + T cell and CXCR4 + CD8 + T cell in MC38-OVA tumours from the 4 treatment groups ( n = 6). g . Boxplot of difference of tVAT area in CR and non-CR patients with T3 or T4 stage separately. The data are presented as a box-and-whisker graph (bounds of box: first to third quartile, bottom and top line: minimum to maximum, central line: median). h . ROC plot of prediction ability of tVAT area in patients with T3 or T4 stage separately. Data represent ≥ 3 independent experiments. P -values were calculated using a two-sided, unpaired Student’s t -test ( b , e - g ) and two-way ANOVA with Tukey’s correction for multiple comparisons ( d ). Graphs display mean ± SD ( b , d , e - g ). Panels created with BioRender : a and c , Huaiqiang, J. https://biorender.com/33r2gmm (2026).

    Article Snippet: The CXCL12 concentrations were determined using the Mouse CXCL12 ELISA kit (R&D system).

    Techniques: Flow Cytometry, Control, Whisker Assay

    a . Experimental design for combination therapy with AMD3100 and αPD-1 in mice bearing MC38-OVA tumours near subcutaneous PAT. b . Representative MC38 tumour images of the mice treated with AMD3100 and/or αPD-1 ( n = 5). c . Representative MC38 tumour weights of the mice treated with AMD3100 and/or αPD-1 ( n = 5). d . Representative MC38 tumour growth of the mice treated with AMD3100 and/or αPD-1 ( n = 5). e . Representative MC38 tumour images in MC38-OVA caecal orthotopic tumour-bearing mice treated with AMD3100 and/or αPD-1 ( n = 5). f . Representative MC38 tumour weights in MC38-OVA caecal orthotopic tumour-bearing mice treated with AMD3100 and/or αPD-1 ( n = 5). g . Representative MC38 Bioluminescence Images in MC38-OVA caecal orthotopic tumour-bearing mice treated with AMD3100 and/or αPD-1 ( n = 5). h . Representative MC38 tumour images in MC38-OVA caecal orthotopic tumour-bearing mice treated with αCXCL12 and/or αPD-1 ( n = 5). i . Representative MC38 tumour weights in MC38-OVA caecal orthotopic tumour-bearing mice treated with αCXCL12 and/or αPD-1 ( n = 5). j . Representative MC38 Bioluminescence Images in MC38-OVA caecal orthotopic tumour-bearing mice treated with αCXCL12 and/or αPD-1 ( n = 5). k . Flow cytometry analysis of the infiltration of immunocytes, including T cells, CD4 + T cells, CD8 + T cells, and tumour-specific CD8 + T cells in MC38-OVA tumours from 4 treatment groups ( n = 5). l . Flow cytometry analysis of the infiltration of CXCR4 + immunocytes, including CXCR4 + T cell, CXCR4 + CD4 + T cell and CXCR4 + CD8 + T cell in MC38-OVA tumours from 4 treatment groups ( n = 5). Data represent ≥ 3 independent experiments. P -values were calculated using a two-sided, unpaired Student’s t -test ( c , f , i , k , l ) and two-way ANOVA with Tukey’s correction for multiple comparisons ( d ). Graphs display mean ± SD ( c - d , f , i , k - l ). Panel created with BioRender : a , Huaiqiang, J. https://biorender.com/wbcolts (2026).

    Journal: Nature Cell Biology

    Article Title: Peritumoural adipose tissue drives immune evasion in colorectal cancer via adipose–mesenchymal transformation

    doi: 10.1038/s41556-026-01885-0

    Figure Lengend Snippet: a . Experimental design for combination therapy with AMD3100 and αPD-1 in mice bearing MC38-OVA tumours near subcutaneous PAT. b . Representative MC38 tumour images of the mice treated with AMD3100 and/or αPD-1 ( n = 5). c . Representative MC38 tumour weights of the mice treated with AMD3100 and/or αPD-1 ( n = 5). d . Representative MC38 tumour growth of the mice treated with AMD3100 and/or αPD-1 ( n = 5). e . Representative MC38 tumour images in MC38-OVA caecal orthotopic tumour-bearing mice treated with AMD3100 and/or αPD-1 ( n = 5). f . Representative MC38 tumour weights in MC38-OVA caecal orthotopic tumour-bearing mice treated with AMD3100 and/or αPD-1 ( n = 5). g . Representative MC38 Bioluminescence Images in MC38-OVA caecal orthotopic tumour-bearing mice treated with AMD3100 and/or αPD-1 ( n = 5). h . Representative MC38 tumour images in MC38-OVA caecal orthotopic tumour-bearing mice treated with αCXCL12 and/or αPD-1 ( n = 5). i . Representative MC38 tumour weights in MC38-OVA caecal orthotopic tumour-bearing mice treated with αCXCL12 and/or αPD-1 ( n = 5). j . Representative MC38 Bioluminescence Images in MC38-OVA caecal orthotopic tumour-bearing mice treated with αCXCL12 and/or αPD-1 ( n = 5). k . Flow cytometry analysis of the infiltration of immunocytes, including T cells, CD4 + T cells, CD8 + T cells, and tumour-specific CD8 + T cells in MC38-OVA tumours from 4 treatment groups ( n = 5). l . Flow cytometry analysis of the infiltration of CXCR4 + immunocytes, including CXCR4 + T cell, CXCR4 + CD4 + T cell and CXCR4 + CD8 + T cell in MC38-OVA tumours from 4 treatment groups ( n = 5). Data represent ≥ 3 independent experiments. P -values were calculated using a two-sided, unpaired Student’s t -test ( c , f , i , k , l ) and two-way ANOVA with Tukey’s correction for multiple comparisons ( d ). Graphs display mean ± SD ( c - d , f , i , k - l ). Panel created with BioRender : a , Huaiqiang, J. https://biorender.com/wbcolts (2026).

    Article Snippet: The CXCL12 concentrations were determined using the Mouse CXCL12 ELISA kit (R&D system).

    Techniques: Flow Cytometry